Genenta Science S.p.A. (GNTA) 6-K 24 Oct 22 Current report (foreign) Financial data

Cover

Cover	6 Months Ended
	Jun. 30, 2022
Cover [Abstract]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-41115
Entity Registrant Name	GENENTA SCIENCE S.P.A.
Entity Central Index Key	0001838716
Entity Address, Address Line One	Via Olgettina No. 58
Entity Address, City or Town	Milan
Entity Address, Country	IT
Entity Address, Postal Zip Code	20132

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - EUR (€)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating expenses
Research and development	€ 1,640,579	€ 3,199,234
General and administrative	2,513,558	842,236
Total operating expenses	4,154,137	4,041,470
Loss from operations	(4,154,137)	(4,041,470)
Other income (expense)
Other income	215,486	2,679
Unrealized exchange rate gain	1,826,330	(9,111)
Total other income (expense)	2,041,816	(6,432)
Loss before income taxes	(2,112,321)	(4,047,902)
Income taxes benefit (expenses)
Net loss	(2,112,321)	(4,047,902)
Net loss and comprehensive loss	(2,112,321)	(4,047,902)
Loss per share:
Loss	€ (2,112,321)	€ (4,047,902)
Loss per share - basic	€ (0.12)	€ (0.27)
Weighted average number of shares outstanding - basic	18,216,858	14,772,610

Consolidated Balance Sheets

Consolidated Balance Sheets - EUR (€)	Jun. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	€ 34,671,156	€ 37,240,162
Prepaid expenses and other current assets	2,737,108	1,519,023
Total current assets	37,408,264	38,759,185
Non-current assets
Property and equipment, net	65,928	23,090
Other non-current asset- related party	3,350	3,350
Other non-current assets	800,000	1,241,215
Total non-current assets	869,278	1,267,655
Total assets	38,277,542	40,026,840
Current liabilities
Accounts payable	247,911	164,819
Accounts payable - related party	277,654	25,047
Accrued expenses	382,862	712,313
Accrued expenses - related party	172,359	132,141
Other current liabilities	120,252	100,719
Total current liabilities	1,201,038	1,135,039
Non-current liabilities
Other non current liabilities	32,407
Retirement benefit obligation	55,192	30,618
Total long-term liabilities	87,599	30,618
Commitments and contingencies
Stockholders’ equity
Common stock, no par value, 59,700,000 shares authorized and 18,216,858 shares issued and outstanding	66,121,033	65,880,990
Accumulated deficit	(29,132,128)	(27,019,807)
Total stockholders’ equity	36,988,905	38,861,183
Total liabilities and stockholders’ equity	€ 38,277,542	€ 40,026,840

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - € / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value	€ 0	€ 0
Common Stock, shares authorized	59,700,000	59,700,000
Common Stock, shares issued	18,216,858	18,216,858
Common Stock, shares outstanding	18,216,858	18,216,858

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Equity - EUR (€)	Corporate Capital [Member]	Additional Paid-in Capital [Member]	Common Stock [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	€ 37,056	€ 36,604,728		€ (21,490,475)	€ 15,151,309
Beginning balance, shares at Dec. 31, 2020
Capital increase from exercise of options on Quota B	715				715
Share-based compensation		497,104			497,104
Quota B repurchased	(172)				(172)
Corporate capital adjustment from Srl to Spa	(37,599)		€ 37,599
Corporate capital adjustment from Srl to Spa, shares			11,279,700
Capital increase related to SpA		(12,401)	€ 12,401
Capital increase related to SpA, shares			3,720,300
Conversion adjustment from Srl to SpA		(37,089,431)	€ 37,089,431
Net loss				(4,047,902)	(4,047,902)
Ending balance, value at Jun. 30, 2021			€ 37,139,431	(25,538,377)	11,601,054
Ending balance, shares at Jun. 30, 2021			15,000,000
Beginning balance, value at Dec. 31, 2021			€ 65,880,990	(27,019,807)	38,861,183
Beginning balance, shares at Dec. 31, 2021			18,216,858
Share-based compensation			€ 240,043		240,043
Net loss				(2,112,321)	(2,112,321)
Ending balance, value at Jun. 30, 2022			€ 66,121,033	€ (29,132,128)	€ 36,988,905
Ending balance, shares at Jun. 30, 2022			18,216,858

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - EUR (€)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Net loss	€ (2,112,321)	€ (4,047,902)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	2,813	2,086
Retirement benefit obligation	24,574	4,256
Share-based compensation	240,043	497,104
Changes in operating assets and liabilities
Prepaid expenses and other current assets	(1,218,085)	(263,548)
Other non-current assets	443,114	(217,757)
Accounts payable	83,092	(274,047)
Accounts payable - related party	252,607	78,365
Accrued expenses	(329,451)	52,602
Accrued expenses - related party	40,218	(549,586)
Other current liabilities	7,203	27,558
Other non current liabilities
Net cash used in operating activities	(2,566,193)	(4,690,869)
Cash flows from investing activities
Purchases of property and equipment	(2,813)	(3,727)
Net cash used in investing activities	(2,813)	(3,727)
Cash flows from financing activities
Proceeds from the exercise of stock options		715
Quota B repurchased		(172)
Prepaid offering costs		(217,284)
Net cash provided by financing activities		(216,741)
Net increase (Net decrease) in cash and cash equivalents	(2,569,006)	(4,911,337)
Cash and cash equivalents at beginning of period	37,240,162	15,465,243
Cash and cash equivalents at end of period	€ 34,671,156	€ 10,553,906

Nature of business and history

Nature of business and history	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of business and history	1. Nature of business and history Genenta Science S.p.A. (the “Company” or “Genenta” - formerly Genenta Science S.r.l., a “società a responsabilità limitata” or “S.r.l,” which is similar to a limited liability company in the United States) converted to an Italian joint stock company (a “società per azioni” or “S.p.A.”) in June 2021, which is similar to a C corporation in the United States. The Company was founded in Milan, Italy by San Raffaele Hospital (“OSR”), Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner, and was incorporated in July 2014. On May 20, 2021, the quotaholders (owners of the Company) resolved that the Company convert from an S.r.l. to an S.p.A. and determined that the outstanding quota be converted to 15 On December 15, 2021, the Company completed an initial public offering (“IPO”) of its ordinary shares and was listed on the Nasdaq Stock Capital Market (“Nasdaq”). Through the IPO, 3,120,114 720,114 2,400,000 96,744 18,216,858 29 3.9 Genenta is an early-stage company developing first-in-class cell and gene cancer therapies. The Company is initially developing its clinical leading product, Temferon™, to treat glioblastoma multiforme (“GBM”), a solid tumor affecting the brain. The Company intends to continue its clinical trials in Europe and eventually start a clinical trial in the United States to study Temferon™ in other cancers, possibly liver cancer. The Company is subject to risks and uncertainties common to early-stage clinical companies in the life-science and biotechnology industries, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new competing products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. The clinical product candidates currently under development will require significant additional research and development efforts, including regulatory approval and clinical testing prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales and profit from operations. Liquidity and risks The Company has incurred losses since its inception, including a net loss of € 2.1 4.0 29.1 34.7 The Company has evaluated whether there are conditions and events considered in the aggregate that raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s business model, typical of biotechnology companies developing new therapeutic products that have not reached a balanced income and financial position, features negative cash flows. This is due to the fact that, at this stage, costs must be borne in relation to services and personnel, directly connected to research and development activities, and return for these activities is not certain and, in any case, it is expected in future years. Based on the accounting policies adopted, requiring full recognition of research and development costs in the statement of operations and comprehensive loss in the year they are incurred, the Company has reported a loss since its inception, and expects to continue to incur significant research and development and clinical costs in the foreseeable future. There is no certainty that the Company will become profitable in the future. The Company will require additional capital to meet its long-term operating requirements. It expects to raise additional capital through, among other things, the sale of equity or debt securities. If adequate funds are not available in the future, the Company may be forced to delay, reorganize, or cancel research and development and/or clinical programs, or to enter into financing, licensing or collaboration agreements with unfavorable conditions or waive rights to certain products which otherwise it would not have waived, resulting in negative effects on the activity and on the economic, patrimonial and /or financial situation of the Company. In February 2020, the COVID-19 pandemic commenced in Italy. Regulatory guidance was issued in March 2020 and updated in April 2020 relating to the management of clinical trials during the pandemic. As the global healthcare community continues to respond to the COVID-19 pandemic, many hospitals, including the Company’s clinical sites, temporarily paused elective medical procedures, including dosing of new patients in clinical trials of our investigational gene therapies. While dosing of new patients and data collection from enrolled patients has resumed at clinical sites, the extent to which clinical activities continue to be delayed or interrupted will depend on future developments that remain uncertain. The Company has not experienced significant interruptions related to COVID-19 or its variants. The Company may find it difficult to enroll patients in its clinical trials, which could delay or prevent the Company from proceeding with clinical trials of its product candidates. The Company continues to closely monitor this evolving situation and the potential impact on the Company. Quantitative and qualitative disclosure about market risk The Company is exposed to market risks in the ordinary course of its business. Market risk represents the risk of loss that may impact the Company’s financial position due to adverse changes in financial market prices and rates. The Company’s current investment policy is conservative due to the need to support operations and, therefore, the Company invests available cash mainly in bank deposits with reputable banks that have a credit rating of at least A-. Accordingly, a substantial majority of the Company’s cash and cash equivalents is held in deposits that bear a small amount of interest. Given the current low rates of interest the Company receives, the Company will not be adversely affected if such rates are changed. The Company’s market risk exposure is primarily a result of foreign currency exchange rates, which is discussed in detail in the following paragraph. Foreign currency exchange risk The Company’s results of operations and cash flow may be subject to fluctuations due to changes in foreign currency exchange rates. The Company’s liquid assets and expenses are denominated in EUR and USD. (At June 30, 2022, the Company maintained $ 22.7 Currently, the Company has recorded an unrealized gain from exchange rate of € 1.8 million. The Company has not yet determined to realize its gain from exchange rate, nor does it currently hedge its foreign currency exchange risk. In the future, the Company may enter into formal currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rates of its principal operating currencies. These measures, however, may not adequately protect the Company from the material adverse effects of such fluctuations.

Summary of significant accounti

Summary of significant accounting policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of significant accounting policies	2. Summary of significant accounting policies Basis of presentation The consolidated financial statements of the Company are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial reporting and in accordance with Regulation S-X, Rule 10-01 promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, the financial statements may not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 20-F filed with the SEC on May 2, 2022. The balance sheet as of December 31, 2021 was derived from audited consolidated financial statements included in the Company’s Annual Report but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these interim financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of the Company’s management, necessary to fairly state the results of the interim period. The interim results are not necessarily indicative of results to be expected for the full year. A summary of the significant accounting policies applied in the preparation of these consolidated financial statements is presented below, only for the categories and headings now applicable and that might be applicable in the future based on the Company’s business. These policies have been consistently applied, unless otherwise stated. Principles of consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts reported in the financial statements and the disclosures made in the accompanying notes. Estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development and clinical expenses and related milestone payments, share-based compensation expense, valuation of research and development tax credits, the valuation of equity and the recoverability of the Company’s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed considering changes in circumstances, facts, and experience. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are recorded in the period in which they become known. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed below. Cash and cash equivalents The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk. In the consolidated cash flow statements, cash and cash equivalents include: cash on hand, deposits held with banks, and other short-term highly liquid investments. In the consolidated balance sheets, bank overdrafts, if any, are shown in current liabilities. Cash and cash equivalents are detailed as follows: Schedule of cash and cash equivalents At June 30, At December 31, 2022 2021 (in Euros) (Unaudited) Cash in bank € 34,667,138 € 37,236,089 Cash in hand & prepaid cards 4,018 4,073 Total € 34,671,156 € 37,240,162 Net loss and comprehensive loss Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. ASC 220 Comprehensive Income requires that an entity records all components of comprehensive (loss) income, net of their related tax effects, in its financial statements in the period in which they are recognized. For the six months ended June 30, 2022, and June 30, 2021, the comprehensive loss was equal to net loss. Net loss per share Net loss per share (“EPS”) is computed in accordance with U.S. GAAP. Basic EPS is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period. Diluted EPS reflects potential dilution and is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period increased by the number of additional ordinary shares that would have been outstanding if all potential ordinary shares had been issued and were dilutive. The EPS calculation was applied at the Company conversion to S.p.A. in June 2021, after the increase in capital to € 50,000 59.7 18,216,858 2.7 147,783 23,502 147,783 Foreign currency translation The reporting and functional currency of the Company is Euros. All amounts are presented in Euros unless otherwise stated. All amounts disclosed in the consolidated financial statements and notes have been rounded to the nearest Euro unless otherwise stated. Foreign currency transactions, if any, are translated into Euros using the exchange rates prevailing at the date(s) of the transaction(s) or valuation where items are re-measured. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the Company’s Consolidated Statements of Operations and Comprehensive Loss. For financial reporting purposes, the assets and liabilities of the US subsidiary are translated into EUR using exchange rates in effect at the balance sheet date. The net loss of the US Subsidiary is translated into EUR using average exchange rates in effect during the reporting period. For the six months ended June 30, 2021, the currency translation impact was insignificant. During the six months ended June 30, 2022, foreign exchange gains unrealized were € 1.8 Emerging growth company status The Company is an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act (the “JOBS Act”) and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company may take advantage of these exemptions until the Company is no longer an “emerging growth company.” Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards and, because of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of its IPO or such earlier time that it is no longer an “emerging growth company.” Fair value measurements Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: ● Level 1 — Quoted prices in active markets for identical assets or liabilities. ● Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. ● Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The carrying values of the Company’s research and development tax credits, VAT credits, accounts payable, accrued expenses and other current liabilities approximate their fair values due to the short-term nature of these assets and liabilities. Segment information Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the Company’s operations and manages its business in one operating segment, which is the research and development in the pharmaceutical sector with a focus on developing novel therapeutics to treat cancer. Tax credit on investments in research and development In line with the legislation in force at December 31, 2021, and for the financial year 2022, companies in Italy that invest in eligible research and development activities, regardless of the legal form and economic sector in which they operate, can benefit from a tax credit which can be used in order to reduce most taxes payable, including income tax or regional tax on productive activities, as well as social security contributions and payroll withholding taxes. For eligible research and development activities, the tax credit is equal to 20 4.0 The eligible activities consist of fundamental research, industrial research, and experimental development as defined respectively of the letters m), q) and j) of point 15, par. 1.3 of the Communication no. 198/2014 of the European Commission. To determine the cost basis of the benefit, the following expenses are eligible: ● Personnel costs; ● Depreciation charges, costs of the financial or simple lease and other expenses related to movable tangible assets and software used in research and development projects; ● Expenses for extra-euro research contracts concerning the direct execution of eligible research and development activities by the provider; ● Expenses for consulting services and equivalent services related to eligible research and development activities; and, ● Expenses for materials, supplies, and other similar products used in research and development projects. The Company, by analogy, accounts for this receivable in accordance with International Accounting Standards (IAS) 20, Accounting for Government Grants and Disclosure of Government Assistance While these tax credits can be carried forward indefinitely, the Company recognized an amount which reflects management’s best estimate of the amount that is reasonably assured to be realized or utilized in the foreseeable future based on historical benefits realized, adjusted for expected changes, as applicable. The tax credits are recorded as an offset to research and development expenses in the Company’s consolidated statements of operations and comprehensive loss. Share-based compensation To reward the efforts of employees, officers, directors, and certain consultants, and to promote the Company’s growth and development, the Company’s Board of Directors may approve, upon occasion, various share-based awards. In May 2021, the Company’s quotaholders adopted the Company’s “Equity Incentive Plan 2021–2025” (“the Plan”); however, through December 31, 2021, no options or awards were granted and there were no outstanding options or awards. (See Note 11. Share-based compensation.) In April 2022, the Company’s Board of Directors, as administrator of the Plan, awarded nonqualified stock options (“NSOs”) on 147,783 Currently, the Company has authorized options on 1,821,685 10 18,216,858 2,700,000 1,821,685 2,700,000 27,000,000 The Company measures its stock option awards granted to employees, officers, directors, and consultants under the Plan based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is normally the vesting period of the respective award. Forfeitures are accounted for as they occur. The measurement date for option awards is the date of the grant. The Company classifies stock-based compensation expense in its Consolidated Statement of Operations and Comprehensive Loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified. The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”) Under paragraphs 718-10-30-7 and 30-9 of Topic 718, there are two ways to determine the fair value of an equity share option (or similar award) at the grant date: 1. If there is an observable market price for an option with the same or similar terms and conditions, that market price shall be the fair value. 2. Otherwise, the fair value of an equity share option or similar instrument (i.e., an instrument with the same time value) must be estimated using a proper valuation technique. In paragraph 718-10-30-8, the FASB indicates that market prices for equity share options and similar instruments are not currently available but could become available in the future. Therefore, in practice, equity share options and similar awards currently are valued using valuation models and techniques. In Section 718-10-55, the FASB explains that the issuer may select from one of the following types of valuation models in determining the fair value of an equity share option: ● A closed-form model that uses an equation to produce an estimated fair value, such as the Black-Scholes-Merton formula; ● A non-closed-form model that produces an estimated fair value on the assumed changes in the prices of a financial instrument over successive periods of time, such as the binomial model or other forms of a lattice model; or ● Other valuation techniques that are not based on a closed-form model, such as a Monte Carlo simulation technique. Topic 718 does not indicate that one valuation technique is better than any other. The FASB hopes this lack of preference will not hinder the future development of better valuation models and techniques. Rather, the FASB explains (in paragraph 718-10-55-17) that each issuer must select an appropriate valuation technique or model depending on the substantive characteristics of the instrument being valued. The SEC reinforced the point that no particular valuation technique or model is preferred in SEC Staff Accounting Bulletin (SAB) Topic 14, “Share-Based Payment” (Codification Section 718-10-S99). Furthermore, FAS 123(R) states that an entity should measure the fair value of a stock option as of the grant date “based on the observable market price of an option with the same or similar terms and conditions, if one is available,” but the FASB further notes that market prices generally are not available. In the absence of such prices, fair value must be “estimated using a valuation technique such as an option-pricing model.” The standard identifies a “lattice model” (e.g., a binomial model) and a “closed-form model” (e.g., the Black-Scholes Merton formula) as acceptable option pricing models and a Monte Carlo simulation technique as another type of acceptable valuation technique. An entity must choose an appropriate valuation technique on the basis of the substantive characteristics of the options it is valuing. The Company chose The Black-Scholes-Merton model because it is considered easier to apply and also it is a defined equation and incorporates only one set of inputs. As a result, it is the model most commonly in use. Representative warrants Upon the closing of the Company’s IPO, the Company issued 23,502 125 14.375 Property and equipment Property and equipment are stated at cost, including any accessory and direct costs that are necessary to make the assets fit for use, and adjusted by the corresponding accumulated depreciation. The depreciation rates recorded in the consolidated financial statements have been calculated by taking into consideration the use, purpose, and financial-technical duration of the assets, on the basis of their estimated useful economic lives. The Company believes the above criteria to be represented by the following estimated useful lives: ● Equipment & furniture: 15 ● Electronic office equipment: 10 ● Leasehold improvements: based on the shorter of the life of the leasehold improvement or the remaining term of the lease. Ordinary maintenance costs are expensed to the consolidated statements of operations and comprehensive loss in the year in which they are incurred. Extraordinary maintenance costs, the purpose of which is to extend the useful economic life of the asset, to technologically upgrade it and/or to increase its productivity or safety for the purpose of economic productivity of the Company, are attributed to the asset to which they refer and depreciated on the basis of its estimated useful economic life. Amortization of leasehold improvements is computed using the straight-line method based upon the terms of the applicable lease or estimated useful life of the improvements, whichever is less. Impairment of long-lived assets In accordance with ASC Topic 360-10-20, ‘‘Property, Plant and Equipment,” the Company performs an impairment test whenever events or circumstances indicate that the carrying value of long-lived assets with finite lives may be impaired. Impairment is measured by comparing the carrying value of the long-lived assets to the estimated undiscounted pre-tax cash flows expected to result from the use of such assets and their ultimate disposition. In circumstances where impairment is determined to exist, the Company will write-down the asset to its fair value based on the present value of estimated cash flows. To date, no impairments have been identified for the six months ended June 30, 2022, and June 30, 2021. Recently issued accounting pronouncements In April 2012, the JOBS Act was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an emerging growth company. As an emerging growth company, the Company may elect to adopt new or revised accounting standards when they become effective for non-public companies, which typically is later than when public companies must adopt the standards. The Company has elected to take advantage of the extended transition period afforded by the JOBS Act and, as a result, unless the Company elects early adoption of any standards, will adopt the new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-public companies. In December 2019, the FASB issued ASU 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes. The new standard intended to simplify the accounting for income taxes by eliminating certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. For non-public entities, the standard is effective for annual periods beginning after December 15, 2021, with early adoption permitted. Adoption of the standard requires certain changes to primarily be made prospectively, with some changes to be made retrospectively. The Company adopted this guidance for the reporting period beginning January 1, 2022, which did not have a material impact on its financial statements or disclosures. In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance. The aim of ASU 2021-10 is to increase the transparency of government assistance including the disclosure of (1) the types of assistance, (2) an entity’s accounting for the assistance, and (3) the effect of the assistance on an entity’s financial statements. Diversity currently exists in the recognition, measurement, presentation, and disclosure of government assistance received by business entities because of the lack of specific authoritative guidance in U.S. GAAP. The ASU will be effective for annual reporting periods after December 15, 2021, and early adoption is permitted. Upon implementation, the Company may use either a prospective or retrospective method of adoption when adopting the ASU. The Company adopted this guidance for the reporting period beginning January 1, 2022, which did not have a material impact on its financial statements or disclosures. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity’s own equity and improves and amends the related EPS guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023, and interim periods within those annual periods and early adoption is permitted in fiscal periods ending after December 15, 2020. Upon implementation, the Company may use either a modified retrospective or full retrospective method of adoption. The Company is evaluating the impact of adopting the new ASU.

Research and development

Research and development	6 Months Ended
	Jun. 30, 2022
Research and Development [Abstract]
Research and development	3. Research and development Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, facilities costs, third-party license fees, and external costs of outside vendors and consultants engaged to conduct clinical development activities and clinical trials, (e.g., contract research organizations [or “CROs”]), as well as costs to develop manufacturing processes, perform analytical testing and manufacture clinical trial materials, (e.g., contract manufacturing organizations [or “CMOs”]). Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered. In addition, funding from research grants, if any, is recognized as an offset to research and development expense based on costs incurred on the research program. The Company annually sustains a significant amount of research costs to meet its business objectives. The Company has various research and development contracts, and the related costs are recorded as research and development expenses as incurred. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations at period end to those third parties. Any accrual estimates are based on several factors, including the Company’s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs. For further details, please refer to the Related Parties disclosures in Note 12 below.

General and administrative

General and administrative	6 Months Ended
	Jun. 30, 2022
General And Administrative
General and administrative	4. General and administrative General and administrative costs consist primarily of salaries, share-based compensation, benefits and other related costs for personnel and consultants in the Company’s executive and finance functions, professional fees for legal, finance, accounting, auditing, tax and consulting services, travel expenses and facility-related expenses, which include rent and maintenance of facilities and other operating costs not otherwise included in research and development expense.

Income taxes

Income taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income taxes	5. Income taxes The Company is subject to taxation in Italy, and with the addition of the Company’s wholly owned subsidiary in the United States, the Company is subject to taxation in the United States. Taxation in Italy includes the standard corporate income tax (“IRES”) and a regional business tax (“IRAP”). Taxation in the United States includes federal corporate income tax (“IRS”), as well as state and local taxes. Taxes are recorded on an accrual basis. They therefore represent the allowances for taxes paid or to be paid for the year, calculated according to the current enacted rates and applicable laws. In the future, the Company may be taxed in various other countries where it may have permanent establishments, as applicable. Due to the tax loss position reported, no income taxes were accrued for the six months ending June 30, 2022, and June 30, 2021, in Italy or the United States. The Company uses the asset and liability method of accounting for deferred income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities, measured at tax rates expected to be enacted at the time of their reversals. These temporary differences primarily relate to net operating losses carried forward available to offset future taxable income. At each reporting date, the Company considers existing evidence, both positive and negative, that could impact its view with regards to future realization of deferred tax assets. In consideration of the start-up status of the Company, a valuation allowance has been established to offset the deferred tax assets, as the related realization is currently uncertain. In the future, should the Company conclude that it is more likely than not that the deferred tax assets are partially or fully realizable, the valuation allowance will be reduced to the extent of such expected realization, and the corresponding amount will be recognized as income tax benefit in the Company’s consolidated statements of operations and comprehensive loss. The Company recognizes tax liabilities from an uncertain tax position if it is more likely than not that the tax position will not be sustained upon examination by the taxing authorities, based on the technical merits of the tax position. There are no uncertain tax positions that have been recognized in the accompanying consolidated financial statements. The prior five years of tax returns (2017-2021) are potentially subject to audit. At June 30, 2022 and June 30, 2021, the Company believes there were no significant differences with regards to its deferred tax assets and its relevant components, compared to the computations of the preceding periods. In 2011, the Italian tax authorities issued a set of rules that modified the previous treatment of tax loss carryforwards. According to the DL 98/2011, at the end of 2011, all existing tax loss carryforwards will never expire but they can off-set only 80% of the taxable income of the year. The rules do not affect the tax loss carryforward that refer to the start-up period, defined as the first three (3) years of operations starting from the inception of the Company. The impact of the updated calculation of tax losses carryforward at December 31, 2021 and 2020 is deemed not significant with respect of the preceding periods. The Company has analyzed its tax position by determining the amount of tax losses that can be carried forward indefinitely and has decided to accrue an allowance for related deferred tax assets as the Company is in a situation of pre-revenues that is destined to remain in the long run and there is no certainty of the future recoverability of such tax losses through tax relevant incomes. Future taxable profits for the Company depend on the manufacture of marketable drugs following the successful completion of the clinical trial. Since the clinical trial is still in Phase I/2a, the time frame and uncertainties regarding the outcome of the completion justify the full allowance of deferred tax assets.

Prepaid expenses and other curr

Prepaid expenses and other current assets	6 Months Ended
	Jun. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid expenses and other current assets	6. Prepaid expenses and other current assets Prepaid expenses and other current assets consist of the following: Schedule of prepaid expenses and other current assets At June 30, At December 31, 2022 2021 (in Euros) (Unaudited) Value Added Tax (VAT) € 1,072,002 € 820,780 Research and development tax credit 800,000 600,000 Advances payments to suppliers 35,401 58,009 Other current assets 180,709 21,987 Other prepaids 648,996 18,247 Total € 2,737,108 € 1,519,023 Value Added Tax (“VAT”) receivables are linked to purchases. Italian VAT ( Imposta sul Valore Aggiunto 22 821,000 1.1 Tax credits on research and development represent a special tax relief offered to Italian companies operating in the research and development sector and can be used to offset most taxes payable. The Company has a total research and development tax credit available to be used of approximately € 4.2 During the six months ended June 30, 2022, the Company utilized approximately € 306,000 204,000 706,000 204,000 Other current assets mainly relate to a tax credit recognized by the Italian Revenue Agency for approximately € 180,000 At June 30, 2022, Other prepaid expenses mainly relate to: i) the directors and officers (“D&O”) insurance policy paid in January 2022 of approximately € 582,000 20,000 30,000

Property and equipment, net

Property and equipment, net	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Property and equipment, net	7. Property and equipment, net Property and equipment consist of the following: Schedule of property and equipment net At June 30, At December 31, 2022 2021 (in Euros) (Unaudited) Computer € 20,353 € 24,869 Auto 49,320 - Furniture and fixtures 10,440 5,010 Total property and equipment 80,113 29,879 Less: accumulated depreciation (14,185 ) (6,789 ) Property and equipment, net € 65,928 € 23,090 Property and equipment consist of computers, an auto, and furniture and fixtures of our office space in Milan, Italy. There were no disposals, nor impairments during the periods. Depreciation has been calculated by taking into consideration the use, purpose, and financial-technical duration of the assets, based on their estimated economic lives. No significant purchases occurred during the six months ended June 30, 2022. Depreciation expense for the six months ending June 30, 2022, and June 30, 2021, were € 2,813 2,086

Other non-current assets

Other non-current assets	6 Months Ended
	Jun. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other non-current assets	8. Other non-current assets Other non-current assets consist as follows: Schedule of other non-current assets At June 30, At December 31, 2022 2021 (in Euros) (Unaudited) Value Added Tax (VAT) € - € 641,215 Research and development tax credit 800,000 600,000 Total € 800,000 € 1,241,215 VAT tax credit at June 30, 2022 is recorded in other current assets. (See Note 6. Prepaid expenses and other current assets.) The research and development tax credit increased due to the increase in the utilization rate. (See Note 6. Prepaid expenses and other current assets.) Other non-current assets - related party includes a security deposit of € 3,350

Retirement benefit obligation

Retirement benefit obligation	6 Months Ended
	Jun. 30, 2022
Retirement Benefits [Abstract]
Retirement benefit obligation	9. Retirement benefit obligation Employees in Italy are entitled to Trattamento di Fine Rapporto (“TFR”), commonly referred to as an employee leaving indemnity, which represents deferred compensation for employees in the private sector. Under Italian law, an entity is obligated to accrue for TFR on an individual employee basis payable to each individual upon termination of employment (including both voluntary and involuntary dismissal). The annual accrual is approximately 7 Compensation – Retirement Benefits 55,192 30,618

Stockholders_ equity

Stockholders’ equity	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Stockholders’ equity	10. Stockholders’ equity The Company was an S.r.l., which is an Italian limited liability company similar to a limited liability company in the United States. The Articles of Incorporation, Shareholders’ Agreement and the By-laws of the Company provided for different quotas, which represented the Company’s corporate capital, rather than shares of stock as ownership corporate capital. As an S.r.l., the Company’s ownership was called “corporate capital” and “quotas” rather than shares, stock, or units. The Company’s capital was divided between the five quotas as summarized below at December 31, 2020: Schedule of company’s capital ownership percentage At December 31, Ownership Quota 2020 % A € 10,458 28 % B 6,886 19 % C 8,645 23 % D 4,034 11 % E 7,033 19 % Total € 37,056 100 % The Company had five (5) quotas: ● Quota A. Quota A was reserved for certain founders. One of the founders had the right to appoint three (3) board members out of five (5), appoint the Chair from these three (3) persons and appoint one (1) member of the Board of Statutory Auditors. One other founder had the right to appoint two (2) board members out of five (5), appoint two (2) statutory auditors and appoint the Chair of the statutory auditors from the two (2) appointees. Quota A had voting rights ● Quota B. Quota B had no voting rights 1.00 ● Quota C. Quota C had the right to appoint one (1) member of the Board of Statutory Auditors; specifically, the one (1) that a founder had the right to appoint. Investors received Quota C in the Company’s first funding round (2014/2015) where approximately € 10 ● Quota D. Investors received Quota D in the Company’s second funding round (2017) where approximately € 7 ● Quota E. Investors received Quota E in the Company’s third funding round (through December 31, 2019) where approximately € 14.8 15.1 0.3 1.4 1.5 0.1 ● Quotas A, C, D & E. During a divestiture proceeding (meaning Quotas representing 100 50 50 During the six months ended June 30, 2021, two events occurred which together had a significant impact on the Company’s equity: On April 1, 2021, the Board of Directors resolved to grant to employees and non-employees stock options and accelerate the vesting of other stock options on € 715 172 543 1 37,771 37,056 715 On May 20, 2021, at a special quotaholders’ meeting, the quotaholders resolved to convert the Company from an S.r.l. to an S.p.A., which conversion became effective on June 18, 2021. As consequence of the conversion, the Corporate Capital has been converted to ordinary shares with no par value and it was increased to € 50,000 As a result of the Company conversion, the Corporate Capital was reclassified as ordinary shares, no par value, combining the minimum capital amount of € 50,000 37,139,431 50,000 15 300 During the six months ended June 30, 2022, no significant events occurred; however, the Company granted a nonqualified fully vested stock option on April 26, 2022, to its chairman at a price based on a sub-plan called “2021-2025 Chairman Sub-Plan. The expense was recorded in the statement of operations and comprehensive loss for the six months ended June 30, 2022, in the amount of € 240,043

Share-based compensation

Share-based compensation	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Share-based compensation	11. Share-based compensation The Company granted options on its corporate capital to certain directors, officers, employees, and consultants, as an incentive and as additional compensation prior to the Company’s conversion to an S.p.A. All options converted into Quota B when vested and exercised. All options had an exercise price of € 1.00 one three In April 2021, € 172 169 546 715 In May 2021, in context of the corporate conversion from a limited liability company (società a responsabilità limitata, or S.r.l.) to a joint stock company (società per azioni, or an S.p.A.), the quotaholders approved a capital increase to allow for issuance of up to 2.7 10 At June 18, 2021, the date of the Company’s conversion to an S.p.A., all stock options were granted, fully vested, exercised and converted into ordinary shares with no par value. At June 30, 2021, there were no outstanding stock options. On April 26, 2022, 147,783 Chairman of the Company at that time, were fully vested and priced based on a sub-plan called “2021-2025 Chairman Sub-Plan” attached to the Plan. Total recognized expense was € 240,043 Schedule of outstanding stock options Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding, vested and expected to vest as of December 31, 2020 546 € 1.00 1.0 € 584,132 Exercisable as of December 31, 2020 - - - - Granted 169 1.00 - 183,831 Vested and exercised 715 1.00 - 777,920 Outstanding, vested and expected to vest as of June 30, 2021 - - - - Exercisable as of June 30, 2021 € - - - € - Outstanding, vested and expected to vest as of January 1, 2022 - - - - Granted and immediately vested 147,783 6.38 2.00 - Vested and exercised Cancelled or forfeited - - - - Outstanding, vested and expected to vest as of June 30, 2022 147,783 6.38 1.82 29,878 Exercisable as of June 30, 2022 € 147,783 € 6.38 1.82 € 29,878 The Company’s share-based compensation expense for the period ended June 30, 2022 and June 30, 2021 is represented by the following table: Schedule of share based compensation expenses Six Months Ended June 30, 2022 2021 Research & development expense € - € 82,669 Research & development expense - related party - 179,480 General & administrative expense 240,043 234,955 Total € 240,043 € 497,104 Unrecognized expense € - € - For the periods ended June 30, 2022, and June 30, 2021, the Company recorded € 240,043 497,104 1.62 1,088 Six months ended June 30, 2022, NSOs Chairman Sub Plan - Valuation At the Board of Directors meeting on April 26, 2022, the Company granted options on 147,783 ● Term: Two ( 2 April 26, 2024 ● Price: € 6.38 ● Vesting: Immediately vested per the Sub-Plan. The Company calculated the stock compensation expense for the options granted to Dr. Squinto by utilizing the Black Scholes method with the following inputs: ● Current stock price (“S t 5.41 ● Strike price (“K”) 6.81 6.38 6.81 1.0674 ● Risk Free Interest Rate (“r”) 18 2.27 ● Expected Term (“t”) 18 ● Volatility (“ ) 82.0 Using the assumptions described above, the estimated fair value of options granted to Dr. Squinto on April 26, 2022 was approximately € 1.62 Therefore, the expense for the fully vested shares was € 240,043 256,222 Six months ended June 30, 2021 - Quota B Valuations The fair value of the Quota B underlying the Company’s stock-based compensation grants had historically been determined by the Company’s board of directors, with input from management and third-party valuations. The Company believes that the board of directors has the relevant experience and expertise to determine the fair value of its Quota B, when also securing third-party assistance. Given the absence of a public trading market of the Company’s equity, and in accordance with the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately- Held Company Equity Securities Issued as Compensation, the board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of the Company’s equity at each grant date. These factors include: ● valuations of the Quota B equity performed by third-party specialists; ● the price of the Company’s equity to third-party, arms-length, sophisticated, and qualified investors; ● the prices, rights, preferences, and privileges of the Company’s Quota C, D, and E preferred equity classes relative to those of the Company’s equity; ● lack of marketability of the Quota B; ● lack of voting rights of the Quota B; ● current business conditions and projections; ● hiring of key personnel and the experience of management; ● the Company’s stage of development; ● the timing, progress and results of the Company’s pre-clinical studies and clinical trials for the Company’s programs and product candidates; including statements regarding the timing of initiation and completion of trials or studies and related preparatory work, the period during which the results of the trials will become available and the Company’s research and development programs; ● likelihood of achieving a liquidity event, such as an initial public offering, a merger or acquisition of the Company given prevailing market conditions, or other liquidation events; ● the market performance of comparable publicly traded companies; and ● the European, U.S. and global capital market conditions. In valuing the Company’s Quota B class of options, the board of directors determined the equity value of the Company’s business using various valuation methods. The board of directors engaged a third-party valuation firm who performed analyses in accordance with the guidance outlined in the American Institute of Certified Public Accountants’ Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. The Company’s option valuations were prepared using an option pricing method (“OPM”), which used market approaches to estimate the Company’s enterprise value. The OPM treats each equity class as a call option on the total equity value of a company, with exercise prices (i.e., breakpoints) based on the value thresholds at which the allocation among the various holders of a company’s securities changes. A discount was considered for Lack of Marketability (“DLOM”), which is an amount or percentage that is deducted from the value in order to reflect the absence of a viable market. The DLOM was then applied to arrive at an indication of value for the option. Also, considered in the valuation was volatility and the fact that the Quota B class of equity did not carry voting rights. The expected volatility used in the OPM is based upon the historical volatility of a number of publicly traded companies in similar stages of clinical development. The weighted average fair value of the options granted during 2021 was € 1,088 Weighted average shares The calculation was performed by taking the number of shares outstanding during a given period and weighting them for the number of days that number of shares were outstanding. For the six months ended June 30, 2022, and June 30, 2021, respectively, there was a weighted average of € 18,216,858 14,772,610 no

Related parties

Related parties	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Related parties	12. Related parties The Company’s research and development expenses are a combination of third-party expenses, and related party expenses, as detailed below: Schedule of third party and related party expenses Six Months Ended June 30, 2022 Third Parties Related Parties Total (in Euros) (Unaudited) Consultants & other third parties € 298,265 € 40,000 € 338,265 Materials & supplies 837,098 - 837,098 Compensation (including share-based) 162,167 215,761 377,928 Travel & entertainment 65,938 - 65,938 Other 21,350 - 21,350 Total € 1,384,818 € 255,761 € 1,640,579 Six Months Ended June 30, 2021 Third Parties Related Parties Total (in Euros) (Unaudited) Consultants & other third parties € 525,978 € 1,541,526 € 2,067,504 Materials & supplies 717,905 - 717,905 Compensation (including share-based) 221,900 179,480 401,380 Travel & entertainment 10,445 - 10,445 Other 2,000 - 2,000 Total € 1,478,228 € 1,721,006 € 3,199,234 Research and development expenses mainly refer to LVV (Lentiviral Vector for Gene therapy) production activities and to preclinical and clinical activities mainly at the San Raffaele Hospital in Milan. Specifically, the related party research and development expenses refer to the costs of preclinical and clinical activities charged by San Raffaele Hospital. The Company’s general and administrative expenses are also a combination of third-party and related party expenses, as detailed below: Schedule of third party and general and administrative expenses Six Months Ended June 30,2022 Third Parties Related Parties Total (In Euros) (Unaudited) Compensation (including share-based) € 522,012 € 421,558 € 943,570 Accounting, legal & other professional 376,642 - 376,642 Facility & insurance related 3,873 7,457 11,330 Consultants & other third parties 384,243 - 384,243 Other 794,248 3,525 797,773 Total € 2,081,018 € 432,540 € 2,513,558 Six Months Ended June 30,2021 Third Parties Related Parties Total (In Euros) (Unaudited) Compensation (including share-based) € 258,514 € 150,000 € 408,514 Accounting, legal & other professional 181,354 - 181,354 Facility & insurance related 1,712 7,197 8,909 Consultants & other third parties 127,988 - 127,988 Other 115,471 - 115,471 Total € 685,039 € 157,197 € 842,236 The Company’s accounts payable to related parties are comprised as follows: Schedule of accounts payable to related parties At June 30, At December 31, 2022 2021 (in Euros) (Unaudited) San Raffaele Hospital € 265,616 € 25,047 Carlo Russo 8,208 - Richard Slansky 3,830 - Total € 277,654 € 25,047 The Company’s accrued expenses to related parties are comprised as follows: Schedule of accrued expenses to related parties At June 30 At December 31 2022 2021 (in Euros) (Unaudited) San Raffaele Hospital (OSR) € 172,359 € 19,201 Executive bonus - 25,000 XDG Biomed - 34,438 Financial consultant - 53,502 Total € 172,359 € 132,141 The increase in San Raffaele Hospital (OSR) account payables balance and accrued expenses compared to December 31, 2021, was due to a delay in the invoicing process by OSR. The Company has identified the following related parties: ● Pierluigi Paracchi ● Luigi Naldini ● Bernard Rudolph Gentner ● Carlo Russo ( ● Richard Slansky ● Spafid S.pA. ( 5 ● Ospedale San Raffaele ( These parties could exercise significant influence on the Company’s strategic decisions, behavior, and future plans. The following is a description of the nature of the transactions between the Company and these related parties: Pierluigi Paracchi Mr. Pierluigi Paracchi, President and Chairman of the Company prior to the conversion, is the current Chief Executive Officer, Vice-Chairman, as well as co-founder. His annual compensation, until December 16, 2021, amounted to € 250,000 50,000 420,000 20 In April 2022, Mr. Paracchi received a bonus of € 50,000 23,000 37,000 For the six months ended June 30, 2022, the Company expensed € 248,242 150,000 For the six months ended June 30, 2022, the Company accrued approximately € 14,000 Luigi Naldini/Bernard Rudolph Gentner Drs. Naldini and Gentner are co-founders of Genenta and part of the SAB – Scientific Advisory Board, with Dr. Naldini as Chairman, and Dr. Gentner as a member. Dr. Naldini has an advisory agreement approved by the Board of Directors and performs the pre-clinical studies for the Company. In particular, the pre-clinical experiments are in solid tumor indications. The agreement with Dr. Naldini, signed in 2019, in place during the six months ended June 30, 2022, provided for an annual fee of € 50,000 25,000 Dr. Gentner, like Dr. Naldini, oversees pre-clinical research related to the Company’s platform technology. In addition, he analyzes clinical biological data. The last agreement with Dr. Gentner, which is still in force, was signed in 2017. His annual fee is € 30,000 15,000 XDG Biomed LLC/Carlo Russo XDG Biomed is the LLC of Dr. Carlo Russo. Dr. Russo has a single contract signed by XDG and the Company that was approved by the Board of Directors and was subject to multiple amendments. In particular, Dr. Russo, via XDG, served as the Company’s Chief Medical Officer and Head of Development pre-IPO. Dr. Russo is responsible for the clinical development of Temferon™, the Company’s gene therapy platform. The recurring fee for Dr. Russo’s services until the IPO date (i.e., December 15, 2021) was € 300,000 50,000 500,000 30 For the six months ended June 30, 2022, and June 30, 2021, the Company expensed € 215,761 175,000 In April 2021, Dr. Russo was awarded a stock option grant, which was immediately vested and exercised, with a value accrued in the Consolidated Statement of Operations and Comprehensive Loss of € 179,480 At December 31, 2021, € 25,000 Richard Slansky Mr. Richard Slansky is the Chief Financial Officer of the Company. He was engaged in late 2020 by the Company to assist with financial, accounting and audit support under an advisory agreement until the end of October 2021. On November 1, 2021, he joined the Company full time and has been employed as Chief Financial Officer. During the six months ended June 30, 2021, by the advisory agreement, Mr. Slansky invoiced Genenta for € 42,224 In April 2021, Mr. Slansky was awarded a stock option grant, which was immediately vested and exercised, with value accrued in the Company’s Consolidated Statement of Operations and Comprehensive Loss of € 54,388 At December 31, 2021, a bonus was accrued, after the success of the IPO, in the amount of $ 50,000 Under the new employment agreement, which started on November 1, 2021, Mr. Slansky is entitled to receive a gross annual compensation of $ 300,000 30 During the six months ended June 30, 2022, the Company recorded a total cost for Mr. Slansky amounting to € 173,317 Spafid SpA Spafid is a Genenta shareholder with an ownership greater than 5 For the six months ended June 30, 2022, Spafid invoiced the Company € 3,525 OSR – San Raffaele Hospital OSR - San Raffaele Hospital is a co-founder of the Company and a shareholder with an ownership greater than 5 License Agreement The Company has a License Agreement with OSR entered in December 2014, for the exclusive use of different patents. In particular, OSR granted the Company an exclusive, world-wide, royalty bearing license under certain technology to conduct research and develop, make, use, import and sell licensed products. The License Agreement covers patents and patent applications, as well as proprietary technologies. The Company’s rights to use these patents and patent applications and to utilize the inventions claimed in these licensed patents are subject to the continuation of, and the Company’s compliance with, the terms of the license agreement. Based on the preclinical studies conducted by OSR, in particular by its SR-TIGET Institute (San Raffaele Telethon Institute for Gene Therapy), on a specific gene therapy strategy with respect to lympho-hematopoietic indication and/or solid cancer indication, the Company decided to develop a new therapy to treat cancer through a cell and gene therapy strategy. The “Field of Use” as defined in the License Agreement is: a) Lympho-Hematopoietic Indication 1 b) Solid Cancer Indication. The agreement provided for an upfront fee of € 250,000 ● option fee on the first indication = € 1.0 0.5 ● option fee on the second indication = € 0.5 ● option fee on the third indication = € 0.3 ● option fee on any additional indications = no license fee. 1 In addition, the Company is obligated make payments on milestones depending on the Field of Use (as defined in the agreement) and pay royalties of 4 In connection to the License Agreement, the Company engaged OSR to provide certain research activities regarding the Licensed Products in the Field of Use, based on a mutually agreed study plan and utilizing the extensive resources at OSR. (See Note 13. Commitments and contingencies.) In consideration of the research activities provided by OSR, the Company agreed to pay scientific collaboration research fees in advance. In December 2014, the Company and OSR signed a Scientific Collaboration Agreement and subsequently modified the Agreement with Research Addenda 1, 2 and 3 in 2016, 2017 and 2018, respectively. During the six months ended June 30, 2022 and June 30, 2021, there were no costs incurred for the above activities. The protocol TEM-GBM_001 received approval by national Competent Authorities in September 2018 and recruited the first patient in April 2019. License Agreement Amendment #2 In February 2019, the Company and OSR entered into Amendment #2 of the License Agreement to conduct a clinical trial according to the protocol TEM-GBM_001 and EudraCT 2018-001404-11 entitled: “A phase I/IIa dose escalation study evaluating the safety and efficacy of autologous CD34+ enriched hematopoietic progenitor cells genetically modified with a lentiviral vector encoding for the human interferon-α2 in patients with GBM who have an unmethylated O-6-methylguanine-DNA methyltransferase gene promoter.” In Amendment #2, the Company and OSR also revised the license fee requirement for the first Solid Cancer indication (GBM). In relation to the GBM trial, the Company and OSR agreed that the Company would be obligated to pay OSR the € 1.0 0.3 0.8 Under Amendment #2, the Company is obligated to cover the costs of the study-related procedures performed on the patients recruited in the Trial, according to periodic study reports delivered by OSR. License Agreement Amendment #3 In December 2020, the Company and OSR entered into Amendment #3 of the License Agreement: The initial € 1.0 0.5 In summary, the Amendment #3 formalized the new arrangement as follows: - exercise of option fee on the first solid cancer indication = € 0.5 - commitment to enter into a Sponsored Research Agreement by February 2021; and, - exercise of option fee on the second indication = € 0.5 At June 30, 2022, no milestones were achieved related to any indication, as provided by License Agreement and subsequent amendments; therefore, no such payments were due to OSR. The Company paid € 1.25 OSR may terminate the Company’s rights as to certain fields of use for the Company’s failure to develop (a) with respect to a solid cancer indication, upon third anniversary of the date the Company exercised such option, if the Company has not filed an IND with respect to such optioned solid cancer indication specifically, as to GBM, the Company is required to file an IND regarding Temferon for GBM prior to February 2022, or (b) with respect to a lympho-hematopoietic indication, on the earlier of (i) the fifth anniversary of the initiation (first patient dosed) of the first human clinical trial for a licensed product in any lympho hematopoietic indication or solid cancer indication if a patient has not been dosed with a licensed product in a Phase 3 clinical trial, or (ii) September 1, 2025. License Agreement Amendment #4 On September 28, 2021, the fourth amendment to the License Agreement was signed with the aim to extend the deadline for the definition of the second Solid Cancer Indication. If the Company is not able to obtain approval of the Regulatory Authorities to initiate a human clinical trial in any country with respect to solid liver cancer on or before September 30, 2022, then the Company shall have the right, at no additional cost, to convert the option exercise for the second Solid Cancer Indication to an indication (the “Alternate Indication”) other than solid liver cancer, upon written notice to OSR, such notice is to be delivered to OSR within September 30, 2022. Under the amendment, the Company will be entitled to exercise the Option set forth above with respect to any other Solid Cancer Indication for the remainder of the Option Period that will expire on December 23, 2022, and shall not be subject to further extensions. At June 30, 2022, the cumulative total amount of expenses for the OSR clinical trial activity from inception amounted to approximately € 9.0 1.0 License Agreement Amendment #5 On January 22, 2022, the fifth amendment to the License Agreement was signed with the aim to clarify certain terms. It has been stated that solely with respect to GBM, “IND” means an investigational new drug application (including any amendment or supplement thereto) submitted to the FDA pursuant to Part 312 of Title 21 of the U.S. Code of Federal Regulations. IND shall include any comparable filing(s) outside the United States of America for the investigation of any product in any other country or group of countries (such as a Clinical Trial Application, or CTA, in the European Union). In addition, with respect to Licensed Products for GBM, Genenta commits to carry out a Phase III Clinical Trial also in US. With respect to GBM, Genenta shall pay to OSR an additional Milestone Payment equal to € 350,000 Moreover with regards to termination rights, if Genenta has not filed an IND with respect to such Solid Cancer Indication within three (3) years from the date of the exercise of the option (or, in relation to GBM, has not dosed the first patient with a Licensed Product for GBM in a Phase III Clinical Trial started in the US within 72 months from the first patient being dosed in the first human clinical trial of such applicable Licensed Product for GBM), the termination rights shall be limited to such Licensed Product in the Terminated Solid Cancer Indication. Any further activity on such Licensed Product in the Terminated Solid Cancer Indication shall be immediately discontinued by Genenta. As of June 30, 2022, no milestones were achieved related to any indication, as provided by the License Agreement; therefore, no payments were due to OSR, nor other contingencies exist Research Funding Agreement In March 2019, the Company and OSR entered a Research Funding Agreement to conduct a clinical trial according to the multiple myeloma protocol, TEM-MM-101 and EudraCT 2018-001741-14, entitled “A Phase I/II dose escalation study evaluating safety and activity of autologous CD34+ enriched hematopoietic progenitor cells genetically modified with a lentiviral vector encoding for the human interferon-α2 in multiple myeloma patients with early relapse after intensive front-line therapy.” This agreement required OSR to perform certain clinical procedures and exploratory analyses on the study population, as per the protocol approved by the relevant competent authorities. The Company was required to fund the costs of the study-related procedures performed on patients recruited in the Trial, according to periodic study reports delivered by OSR. TEM-MM-101 received approval by national Competent Authorities in November 2018 and the first TEM-MM-101 trial patient was enrolled in August 2019. The Company discontinued the multiple myeloma program in early 2021 due to the relatively small number of eligible patients, and the highly competitive MM landscape. (See Note 13.) Sponsor Research Agreement (SRA) As stated above, in exchange for a reduction in the first Solid Cancer indication option fee from € 1.0 0.5 0.5 1.0 0.5 ● Research 1: Additional preclinical mouse model studies directed to identify Temferon effectors cells (transduced Tie2-expressing cells) and to test Temferon in combination with CAR-T in a GBM mouse model; and, ● Research 2: Additional exploratory analyses, including single cell sequencing, to be conducted on samples collected from patients belonging to TEM-GBM_001 clinical trial aimed to deepen Temferon mechanism of action and get a broader insight on its biological activity in humans. For the six months ended June 30, 2022, and June 30, 2021, the Company paid and expensed € 375,000 500,000 Amendment #01 to the Agreement of March 2, 2019 On April 27, 2022 OSR and Genenta signed this Amendment #01 as an amendment to the Agreement for Clinical Trials called: “ Phase I/IIa clinical trial to assess the safety and efficacy of increasing doses of autologous CD34+ hematopoietic stem cells genetically modified with a lentiviral vector encoding for the human interferon-alpha2 gene in patients with Glioblastoma Multiforme with unmethylated MGMT gene promoter ● TEM-MM unspent budget to be reallocated to the TEM-GBM study: ● Investigator € 105,000 ● Data Manager € 92,500 ● Total € 197,500 During the six months ended June 30, 2022, the Company recorded expenses of € 105,551 Operating leases The Company entered into a non-cancelable lease agreement for office space in January 2020. (See Note 13. Commitments and contingencies.)

Commitments and contingencies

Commitments and contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	13. Commitments and contingencies The Company exercises considerable judgment in determining the exposure to risks and recognizing provisions or providing disclosure for contingent liabilities related to pending litigations or other outstanding claims and liabilities. Judgment is necessary in assessing the likelihood that a pending claim will succeed, or a liability will arise and to quantify the possible range of the final settlement. Provisions are recorded for liabilities when losses are considered probable and can be reasonably estimated. Because of the inherent uncertainties in making such judgments, actual losses may be different from the originally estimated provision. Estimates are subject to change as new information becomes available, primarily with the support of internal specialists or outside consultants, such as actuaries or legal counsel. Adjustments to provisions may significantly affect future operating results. The following table summarizes the Company obligations by contractual maturity on June 30, 2022: Schedule of company obligations by contractual maturity Payments by Period (in Euros) Total Less than a year 1 to 3 years 4 to 5 years More than 5 years OSR operating leases and office rent € 33,500 € 13,400 € 20,100 € - € - AGC manufacturing 83,200 8,050 58,150 17,000 - Insurances on operating leases 25,653 6,996 18,657 - - Total € 142,353 € 28,446 € 96,907 € 17,000 € - The commitments with OSR relate to the office rent agreement while the commitments with AGC Biologics (“AGC”) relate to biologic stability studies on plasmid batches. Insurances on operating leases are related to the non-lease insurance component of BMW car leasing agreement, which was entered into in February 2022 and has a term of four (4) years. The Company has not included future milestones and royalty payments in the table above because the payment obligations under these agreements are contingent upon future events, such as the Company’s achievement of specified milestones or generating product sales, and the amount, timing and likelihood of such payments are unknown and are not yet considered probable. CMOs and CROs agreements The Company enters into contracts in the normal course of business with CMOs, CROs and other third parties for exploratory studies, manufacturing, clinical trials, testing, and services (shipments, travel logistics, etc.). These contracts do not contain minimum purchase commitments and, except as discussed below, are cancelable by the Company upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including non-cancelable obligations of the Company’s vendors or third-party service providers, up to the date of cancellation. These payments are not included in the table above as the amount and timing of such payments are not known. OSR - San Raffaele Hospital The License Agreement in place with OSR provides for milestone payments and royalties. The OSR agreements are non-cancelable, except in the case of breach of contract, and includes total potential milestone payments of up to € 10 53 7.0 3.5 Glioblastoma multiforme (GBM) As discussed in Note 12, in December 2020, the Company had one indication ongoing, GBM. The Company’s contingent liability for this first solid cancer indication potentially payable to OSR was € 53 Liver cancer (LC) In relation to the option exercised by the Company for the second solid cancer indication, the Company and OSR agreed that the payment due in relation to the “First patient dosed with a Licensed Product in Phase I/II Clinical Trial,” as stated in the agreement, was reduced to € 0.5 1.0 5.0 47.5 The agreements also include a € 7.8 million commitment related to the development and manufacturing of licensed products, of which the Company had incurred € 0.8 million and € 0.7 million of expenses during the first six months ended June 30, 2022 and June 30, 2021, respectively. The cumulative expense to date is € 6.2 million. AGC Biologics (formerly MolMed) The AGC agreement is non-cancelable, except in the case of breach of contract, and includes a potential milestone of € 0.3 0.5 1.0 0.5 1.0 360,000 259,000 41,000 259,000 20 17,000 GMP 311,280 GMP 311,280 272,800 In early 2020, the Company and AGC amended the Master Service Agreement for the fourth time to regulate some new production activities for which the total estimated budget amounts to € 0.3 32,200 In September 2021, the Company extended the stability studies on the plasmid batch pIFNa 16024 (p906) up to nine (9) years and at June 30, 2021, the Company was committed to pay a total of € 51,000 83,200 Operating lease - office rent On January 1, 2020, the Company began a six-year non-cancelable lease agreement for office space with OSR. Withdrawal is allowed from the fourth year with a notice of 12 months. Since the annual rent amounts to € 13,400 6,700 Capital lease On February 11, 2022, the Company entered into a four (4) year car lease. This lease has been recognized as a capital lease. For the six months ended June 30, 2022, the Company recorded in the Consolidated Statement of Operations and Comprehensive amortization expenses of € 4,583 On June 30, 2022, the Company recorded € 44,737 12,330 32,407 The car underling the lease agreement is fully covered by insurance policies for the duration of the lease agreement, for a total amount of € 27,985 2,332 25,653 Legal proceedings The Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of ASC 450, Contingencies. The Company was notified by Theravectys of the possible infringement by the Company of Theravectys’ exclusive license to patents no. EP 1071804, EP 1224314, and EP 1222300 granted from the owner of the patents Institut Pasteur. Each of these patents is now expired, having each reached the end of it its patent term on April 23, 2019 for EP 1071804 and October 10, 2020 for EP 1224314, and EP 1222300. The Company considered the situation and determined that the likelihood of a material adverse effect on its business is remote. To date, the Company has not engaged in any such discussions with Theravectys nor has the Company received any further communication from Theravectys. The Company expenses, as incurred, the costs related to its legal proceedings, if any. Coronavirus Pandemic On March 11, 2020, the World Health Organization declared the outbreak of the coronavirus (COVID-19) pandemic. Significant uncertainties may arise with respect to potential shutdowns of operations or government orders to cease activities due to emergency declarations, inability to operate, or employee shortages, claims for business interruption insurance, etc. Although the Company has experienced minimal disruption to date and still has staff working remotely from home, the Company may find it difficult to enroll patients in its clinical trials, which could delay or prevent the Company from proceeding with the clinical trials of its product candidates; therefore, the coronavirus pandemic may still have a significant impact on the future results of the Company.

Subsequent events

Subsequent events	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent events	14. Subsequent events Board Resignations On July 7, 2022, and July 8, 2022, Dr. Daniela Bellomo and Dr. Luca Guidotti, respectively, resigned from the Board. Dr. ’s and Dr. ’s resignations did not result from any disagreements with management or the Board. Stock Option Grant Nonqualified stock options on 392,740 OSR Letter Agreement On September 29, 2022, the Company entered into a letter agreement with OSR to extend each of the alternative indication notice period (as defined by the Amendment 4 to the License Agreement) and the competing product period (as defined in the Amendment 3 to the License Agreement) to December 23, 2022.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The consolidated financial statements of the Company are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial reporting and in accordance with Regulation S-X, Rule 10-01 promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, the financial statements may not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 20-F filed with the SEC on May 2, 2022. The balance sheet as of December 31, 2021 was derived from audited consolidated financial statements included in the Company’s Annual Report but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these interim financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of the Company’s management, necessary to fairly state the results of the interim period. The interim results are not necessarily indicative of results to be expected for the full year. A summary of the significant accounting policies applied in the preparation of these consolidated financial statements is presented below, only for the categories and headings now applicable and that might be applicable in the future based on the Company’s business. These policies have been consistently applied, unless otherwise stated.
Principles of consolidation	Principles of consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of estimates	Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts reported in the financial statements and the disclosures made in the accompanying notes. Estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development and clinical expenses and related milestone payments, share-based compensation expense, valuation of research and development tax credits, the valuation of equity and the recoverability of the Company’s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed considering changes in circumstances, facts, and experience. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are recorded in the period in which they become known. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed below.
Cash and cash equivalents	Cash and cash equivalents The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk. In the consolidated cash flow statements, cash and cash equivalents include: cash on hand, deposits held with banks, and other short-term highly liquid investments. In the consolidated balance sheets, bank overdrafts, if any, are shown in current liabilities. Cash and cash equivalents are detailed as follows: Schedule of cash and cash equivalents At June 30, At December 31, 2022 2021 (in Euros) (Unaudited) Cash in bank € 34,667,138 € 37,236,089 Cash in hand & prepaid cards 4,018 4,073 Total € 34,671,156 € 37,240,162
Net loss and comprehensive loss	Net loss and comprehensive loss Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. ASC 220 Comprehensive Income requires that an entity records all components of comprehensive (loss) income, net of their related tax effects, in its financial statements in the period in which they are recognized. For the six months ended June 30, 2022, and June 30, 2021, the comprehensive loss was equal to net loss.
Net loss per share	Net loss per share Net loss per share (“EPS”) is computed in accordance with U.S. GAAP. Basic EPS is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period. Diluted EPS reflects potential dilution and is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period increased by the number of additional ordinary shares that would have been outstanding if all potential ordinary shares had been issued and were dilutive. The EPS calculation was applied at the Company conversion to S.p.A. in June 2021, after the increase in capital to € 50,000 59.7 18,216,858 2.7 147,783 23,502 147,783
Foreign currency translation	Foreign currency translation The reporting and functional currency of the Company is Euros. All amounts are presented in Euros unless otherwise stated. All amounts disclosed in the consolidated financial statements and notes have been rounded to the nearest Euro unless otherwise stated. Foreign currency transactions, if any, are translated into Euros using the exchange rates prevailing at the date(s) of the transaction(s) or valuation where items are re-measured. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the Company’s Consolidated Statements of Operations and Comprehensive Loss. For financial reporting purposes, the assets and liabilities of the US subsidiary are translated into EUR using exchange rates in effect at the balance sheet date. The net loss of the US Subsidiary is translated into EUR using average exchange rates in effect during the reporting period. For the six months ended June 30, 2021, the currency translation impact was insignificant. During the six months ended June 30, 2022, foreign exchange gains unrealized were € 1.8
Emerging growth company status	Emerging growth company status The Company is an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act (the “JOBS Act”) and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company may take advantage of these exemptions until the Company is no longer an “emerging growth company.” Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards and, because of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of its IPO or such earlier time that it is no longer an “emerging growth company.”
Fair value measurements	Fair value measurements Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: ● Level 1 — Quoted prices in active markets for identical assets or liabilities. ● Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. ● Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The carrying values of the Company’s research and development tax credits, VAT credits, accounts payable, accrued expenses and other current liabilities approximate their fair values due to the short-term nature of these assets and liabilities.
Segment information	Segment information Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the Company’s operations and manages its business in one operating segment, which is the research and development in the pharmaceutical sector with a focus on developing novel therapeutics to treat cancer.
Tax credit on investments in research and development	Tax credit on investments in research and development In line with the legislation in force at December 31, 2021, and for the financial year 2022, companies in Italy that invest in eligible research and development activities, regardless of the legal form and economic sector in which they operate, can benefit from a tax credit which can be used in order to reduce most taxes payable, including income tax or regional tax on productive activities, as well as social security contributions and payroll withholding taxes. For eligible research and development activities, the tax credit is equal to 20 4.0 The eligible activities consist of fundamental research, industrial research, and experimental development as defined respectively of the letters m), q) and j) of point 15, par. 1.3 of the Communication no. 198/2014 of the European Commission. To determine the cost basis of the benefit, the following expenses are eligible: ● Personnel costs; ● Depreciation charges, costs of the financial or simple lease and other expenses related to movable tangible assets and software used in research and development projects; ● Expenses for extra-euro research contracts concerning the direct execution of eligible research and development activities by the provider; ● Expenses for consulting services and equivalent services related to eligible research and development activities; and, ● Expenses for materials, supplies, and other similar products used in research and development projects. The Company, by analogy, accounts for this receivable in accordance with International Accounting Standards (IAS) 20, Accounting for Government Grants and Disclosure of Government Assistance While these tax credits can be carried forward indefinitely, the Company recognized an amount which reflects management’s best estimate of the amount that is reasonably assured to be realized or utilized in the foreseeable future based on historical benefits realized, adjusted for expected changes, as applicable. The tax credits are recorded as an offset to research and development expenses in the Company’s consolidated statements of operations and comprehensive loss.
Share-based compensation	Share-based compensation To reward the efforts of employees, officers, directors, and certain consultants, and to promote the Company’s growth and development, the Company’s Board of Directors may approve, upon occasion, various share-based awards. In May 2021, the Company’s quotaholders adopted the Company’s “Equity Incentive Plan 2021–2025” (“the Plan”); however, through December 31, 2021, no options or awards were granted and there were no outstanding options or awards. (See Note 11. Share-based compensation.) In April 2022, the Company’s Board of Directors, as administrator of the Plan, awarded nonqualified stock options (“NSOs”) on 147,783 Currently, the Company has authorized options on 1,821,685 10 18,216,858 2,700,000 1,821,685 2,700,000 27,000,000 The Company measures its stock option awards granted to employees, officers, directors, and consultants under the Plan based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is normally the vesting period of the respective award. Forfeitures are accounted for as they occur. The measurement date for option awards is the date of the grant. The Company classifies stock-based compensation expense in its Consolidated Statement of Operations and Comprehensive Loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified. The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”) Under paragraphs 718-10-30-7 and 30-9 of Topic 718, there are two ways to determine the fair value of an equity share option (or similar award) at the grant date: 1. If there is an observable market price for an option with the same or similar terms and conditions, that market price shall be the fair value. 2. Otherwise, the fair value of an equity share option or similar instrument (i.e., an instrument with the same time value) must be estimated using a proper valuation technique. In paragraph 718-10-30-8, the FASB indicates that market prices for equity share options and similar instruments are not currently available but could become available in the future. Therefore, in practice, equity share options and similar awards currently are valued using valuation models and techniques. In Section 718-10-55, the FASB explains that the issuer may select from one of the following types of valuation models in determining the fair value of an equity share option: ● A closed-form model that uses an equation to produce an estimated fair value, such as the Black-Scholes-Merton formula; ● A non-closed-form model that produces an estimated fair value on the assumed changes in the prices of a financial instrument over successive periods of time, such as the binomial model or other forms of a lattice model; or ● Other valuation techniques that are not based on a closed-form model, such as a Monte Carlo simulation technique. Topic 718 does not indicate that one valuation technique is better than any other. The FASB hopes this lack of preference will not hinder the future development of better valuation models and techniques. Rather, the FASB explains (in paragraph 718-10-55-17) that each issuer must select an appropriate valuation technique or model depending on the substantive characteristics of the instrument being valued. The SEC reinforced the point that no particular valuation technique or model is preferred in SEC Staff Accounting Bulletin (SAB) Topic 14, “Share-Based Payment” (Codification Section 718-10-S99). Furthermore, FAS 123(R) states that an entity should measure the fair value of a stock option as of the grant date “based on the observable market price of an option with the same or similar terms and conditions, if one is available,” but the FASB further notes that market prices generally are not available. In the absence of such prices, fair value must be “estimated using a valuation technique such as an option-pricing model.” The standard identifies a “lattice model” (e.g., a binomial model) and a “closed-form model” (e.g., the Black-Scholes Merton formula) as acceptable option pricing models and a Monte Carlo simulation technique as another type of acceptable valuation technique. An entity must choose an appropriate valuation technique on the basis of the substantive characteristics of the options it is valuing. The Company chose The Black-Scholes-Merton model because it is considered easier to apply and also it is a defined equation and incorporates only one set of inputs. As a result, it is the model most commonly in use.
Representative warrants	Representative warrants Upon the closing of the Company’s IPO, the Company issued 23,502 125 14.375
Property and equipment	Property and equipment Property and equipment are stated at cost, including any accessory and direct costs that are necessary to make the assets fit for use, and adjusted by the corresponding accumulated depreciation. The depreciation rates recorded in the consolidated financial statements have been calculated by taking into consideration the use, purpose, and financial-technical duration of the assets, on the basis of their estimated useful economic lives. The Company believes the above criteria to be represented by the following estimated useful lives: ● Equipment & furniture: 15 ● Electronic office equipment: 10 ● Leasehold improvements: based on the shorter of the life of the leasehold improvement or the remaining term of the lease. Ordinary maintenance costs are expensed to the consolidated statements of operations and comprehensive loss in the year in which they are incurred. Extraordinary maintenance costs, the purpose of which is to extend the useful economic life of the asset, to technologically upgrade it and/or to increase its productivity or safety for the purpose of economic productivity of the Company, are attributed to the asset to which they refer and depreciated on the basis of its estimated useful economic life. Amortization of leasehold improvements is computed using the straight-line method based upon the terms of the applicable lease or estimated useful life of the improvements, whichever is less.
Impairment of long-lived assets	Impairment of long-lived assets In accordance with ASC Topic 360-10-20, ‘‘Property, Plant and Equipment,” the Company performs an impairment test whenever events or circumstances indicate that the carrying value of long-lived assets with finite lives may be impaired. Impairment is measured by comparing the carrying value of the long-lived assets to the estimated undiscounted pre-tax cash flows expected to result from the use of such assets and their ultimate disposition. In circumstances where impairment is determined to exist, the Company will write-down the asset to its fair value based on the present value of estimated cash flows. To date, no impairments have been identified for the six months ended June 30, 2022, and June 30, 2021.
Recently issued accounting pronouncements	Recently issued accounting pronouncements In April 2012, the JOBS Act was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an emerging growth company. As an emerging growth company, the Company may elect to adopt new or revised accounting standards when they become effective for non-public companies, which typically is later than when public companies must adopt the standards. The Company has elected to take advantage of the extended transition period afforded by the JOBS Act and, as a result, unless the Company elects early adoption of any standards, will adopt the new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-public companies. In December 2019, the FASB issued ASU 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes. The new standard intended to simplify the accounting for income taxes by eliminating certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. For non-public entities, the standard is effective for annual periods beginning after December 15, 2021, with early adoption permitted. Adoption of the standard requires certain changes to primarily be made prospectively, with some changes to be made retrospectively. The Company adopted this guidance for the reporting period beginning January 1, 2022, which did not have a material impact on its financial statements or disclosures. In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance. The aim of ASU 2021-10 is to increase the transparency of government assistance including the disclosure of (1) the types of assistance, (2) an entity’s accounting for the assistance, and (3) the effect of the assistance on an entity’s financial statements. Diversity currently exists in the recognition, measurement, presentation, and disclosure of government assistance received by business entities because of the lack of specific authoritative guidance in U.S. GAAP. The ASU will be effective for annual reporting periods after December 15, 2021, and early adoption is permitted. Upon implementation, the Company may use either a prospective or retrospective method of adoption when adopting the ASU. The Company adopted this guidance for the reporting period beginning January 1, 2022, which did not have a material impact on its financial statements or disclosures. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity’s own equity and improves and amends the related EPS guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023, and interim periods within those annual periods and early adoption is permitted in fiscal periods ending after December 15, 2020. Upon implementation, the Company may use either a modified retrospective or full retrospective method of adoption. The Company is evaluating the impact of adopting the new ASU.

Summary of significant accoun_3

Summary of significant accounting policies (Tables)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Schedule of cash and cash equivalents	Schedule of cash and cash equivalents At June 30, At December 31, 2022 2021 (in Euros) (Unaudited) Cash in bank € 34,667,138 € 37,236,089 Cash in hand & prepaid cards 4,018 4,073 Total € 34,671,156 € 37,240,162

Prepaid expenses and other cu_2

Prepaid expenses and other current assets (Tables)	6 Months Ended
	Jun. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of prepaid expenses and other current assets	Prepaid expenses and other current assets consist of the following: Schedule of prepaid expenses and other current assets At June 30, At December 31, 2022 2021 (in Euros) (Unaudited) Value Added Tax (VAT) € 1,072,002 € 820,780 Research and development tax credit 800,000 600,000 Advances payments to suppliers 35,401 58,009 Other current assets 180,709 21,987 Other prepaids 648,996 18,247 Total € 2,737,108 € 1,519,023

Property and equipment, net (Ta

Property and equipment, net (Tables)	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of property and equipment net	Property and equipment consist of the following: Schedule of property and equipment net At June 30, At December 31, 2022 2021 (in Euros) (Unaudited) Computer € 20,353 € 24,869 Auto 49,320 - Furniture and fixtures 10,440 5,010 Total property and equipment 80,113 29,879 Less: accumulated depreciation (14,185 ) (6,789 ) Property and equipment, net € 65,928 € 23,090

Other non-current assets (Table

Other non-current assets (Tables)	6 Months Ended
	Jun. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of other non-current assets	Other non-current assets consist as follows: Schedule of other non-current assets At June 30, At December 31, 2022 2021 (in Euros) (Unaudited) Value Added Tax (VAT) € - € 641,215 Research and development tax credit 800,000 600,000 Total € 800,000 € 1,241,215

Stockholders_ equity (Tables)

Stockholders’ equity (Tables)	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Schedule of company’s capital ownership percentage	The Company’s capital was divided between the five quotas as summarized below at December 31, 2020: Schedule of company’s capital ownership percentage At December 31, Ownership Quota 2020 % A € 10,458 28 % B 6,886 19 % C 8,645 23 % D 4,034 11 % E 7,033 19 % Total € 37,056 100 %

Share-based compensation (Table

Share-based compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of outstanding stock options	Schedule of outstanding stock options Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding, vested and expected to vest as of December 31, 2020 546 € 1.00 1.0 € 584,132 Exercisable as of December 31, 2020 - - - - Granted 169 1.00 - 183,831 Vested and exercised 715 1.00 - 777,920 Outstanding, vested and expected to vest as of June 30, 2021 - - - - Exercisable as of June 30, 2021 € - - - € - Outstanding, vested and expected to vest as of January 1, 2022 - - - - Granted and immediately vested 147,783 6.38 2.00 - Vested and exercised Cancelled or forfeited - - - - Outstanding, vested and expected to vest as of June 30, 2022 147,783 6.38 1.82 29,878 Exercisable as of June 30, 2022 € 147,783 € 6.38 1.82 € 29,878
Schedule of share based compensation expenses	The Company’s share-based compensation expense for the period ended June 30, 2022 and June 30, 2021 is represented by the following table: Schedule of share based compensation expenses Six Months Ended June 30, 2022 2021 Research & development expense € - € 82,669 Research & development expense - related party - 179,480 General & administrative expense 240,043 234,955 Total € 240,043 € 497,104 Unrecognized expense € - € -

Related parties (Tables)

Related parties (Tables)	6 Months Ended
	Jun. 30, 2022
Schedule of accounts payable to related parties	The Company’s accounts payable to related parties are comprised as follows: Schedule of accounts payable to related parties At June 30, At December 31, 2022 2021 (in Euros) (Unaudited) San Raffaele Hospital € 265,616 € 25,047 Carlo Russo 8,208 - Richard Slansky 3,830 - Total € 277,654 € 25,047
Schedule of accrued expenses to related parties	The Company’s accrued expenses to related parties are comprised as follows: Schedule of accrued expenses to related parties At June 30 At December 31 2022 2021 (in Euros) (Unaudited) San Raffaele Hospital (OSR) € 172,359 € 19,201 Executive bonus - 25,000 XDG Biomed - 34,438 Financial consultant - 53,502 Total € 172,359 € 132,141
Research and Development Expense [Member]
Schedule of third party and general and administrative expenses	The Company’s research and development expenses are a combination of third-party expenses, and related party expenses, as detailed below: Schedule of third party and related party expenses Six Months Ended June 30, 2022 Third Parties Related Parties Total (in Euros) (Unaudited) Consultants & other third parties € 298,265 € 40,000 € 338,265 Materials & supplies 837,098 - 837,098 Compensation (including share-based) 162,167 215,761 377,928 Travel & entertainment 65,938 - 65,938 Other 21,350 - 21,350 Total € 1,384,818 € 255,761 € 1,640,579 Six Months Ended June 30, 2021 Third Parties Related Parties Total (in Euros) (Unaudited) Consultants & other third parties € 525,978 € 1,541,526 € 2,067,504 Materials & supplies 717,905 - 717,905 Compensation (including share-based) 221,900 179,480 401,380 Travel & entertainment 10,445 - 10,445 Other 2,000 - 2,000 Total € 1,478,228 € 1,721,006 € 3,199,234
General and Administrative Expense [Member]
Schedule of third party and general and administrative expenses	The Company’s general and administrative expenses are also a combination of third-party and related party expenses, as detailed below: Schedule of third party and general and administrative expenses Six Months Ended June 30,2022 Third Parties Related Parties Total (In Euros) (Unaudited) Compensation (including share-based) € 522,012 € 421,558 € 943,570 Accounting, legal & other professional 376,642 - 376,642 Facility & insurance related 3,873 7,457 11,330 Consultants & other third parties 384,243 - 384,243 Other 794,248 3,525 797,773 Total € 2,081,018 € 432,540 € 2,513,558 Six Months Ended June 30,2021 Third Parties Related Parties Total (In Euros) (Unaudited) Compensation (including share-based) € 258,514 € 150,000 € 408,514 Accounting, legal & other professional 181,354 - 181,354 Facility & insurance related 1,712 7,197 8,909 Consultants & other third parties 127,988 - 127,988 Other 115,471 - 115,471 Total € 685,039 € 157,197 € 842,236

Commitments and contingencies (

Commitments and contingencies (Tables)	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of company obligations by contractual maturity	The following table summarizes the Company obligations by contractual maturity on June 30, 2022: Schedule of company obligations by contractual maturity Payments by Period (in Euros) Total Less than a year 1 to 3 years 4 to 5 years More than 5 years OSR operating leases and office rent € 33,500 € 13,400 € 20,100 € - € - AGC manufacturing 83,200 8,050 58,150 17,000 - Insurances on operating leases 25,653 6,996 18,657 - - Total € 142,353 € 28,446 € 96,907 € 17,000 € -

Nature of business and history

Nature of business and history (Details Narrative) - EUR (€)				6 Months Ended
	Dec. 27, 2021	Dec. 15, 2021	May 20, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Subsidiary, Sale of Stock [Line Items]
Conversion of stock, shares issued			15,000,000
Number of shares issued		2,400,000
Number of ordinary shares subscribed		720,114
Common stock, shares, outstanding				18,216,858		18,216,858
Sale of stock, net of listing costs		€ 3,900,000
Net loss				€ 2,112,321	€ 4,047,902
Accumulated deficit				29,132,128		€ 27,019,807
Cash and cash equivalents				34,671,156		€ 37,240,162
Foreign Currency Transaction Gain (Loss), Unrealized				1,826,330	€ (9,111)
Foreign Exchange [Member]
Subsidiary, Sale of Stock [Line Items]
Cash and cash equivalents				€ 22,700,000
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued		3,120,114
Sale of stock, net of listing costs		€ 29,000,000
Over-Allotment Option [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares exercised	96,744

Schedule of cash and cash equiv

Schedule of cash and cash equivalents (Details) - EUR (€)	Jun. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Cash in bank	€ 34,667,138	€ 37,236,089
Cash in hand & prepaid cards	4,018	4,073
Total	€ 34,671,156	€ 37,240,162

Summary of significant accoun_4

Summary of significant accounting policies (Details Narrative) - EUR (€)			1 Months Ended			6 Months Ended		12 Months Ended
	Dec. 15, 2021	May 20, 2021	Apr. 30, 2022	Jun. 30, 2021	May 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Share capital increased				€ 50,000
Common stock, shares authorized						59,700,000		59,700,000
Common stock, shares, issued						18,216,858		18,216,858
Common stock, shares, outstanding						18,216,858		18,216,858
Number of options shares outstanding						147,783
Foreign exchange gains unrealized						€ 1,826,330	€ (9,111)
Tax credit on investments in research and development, percentage						20%		20%
Tax credit on investments in research and development, annual amount						€ 4,200,000
Number of shares awarded			147,783
Number of shares outstanding, percentage					10%
Number of shares issued	2,400,000
Equipment And Furniture [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives						15 years
Electronic Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives						10 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives, description						based on the shorter of the life of the leasehold improvement or the remaining term of the lease.
Common Stock [Member]
Property, Plant and Equipment [Line Items]
Number of shares outstanding				15,000,000		18,216,858	15,000,000	18,216,858
Warrant [Member]
Property, Plant and Equipment [Line Items]
Number of shares issued						23,502
Exercisable percentage of warrant						125%
Exercise price, per share						€ 14.375
Share-Based Payment Arrangement, Option [Member] | Common Stock [Member]
Property, Plant and Equipment [Line Items]
Number of options shares outstanding						18,216,858
Number of shares authorized						1,821,685
Number of shares outstanding, percentage						10%
Maximum [Member]
Property, Plant and Equipment [Line Items]
Tax credit on investments in research and development, annual amount						€ 4,000,000		€ 4,000,000
Maximum [Member] | Common Stock [Member]
Property, Plant and Equipment [Line Items]
Share-based payment award, options, number of shares, period increase		2,700,000
Number of shares available for issuance		2,700,000
Number of shares outstanding						27,000,000
Minimum [Member] | Common Stock [Member]
Property, Plant and Equipment [Line Items]
Number of shares available for issuance		1,821,685
Warrant [Member]
Property, Plant and Equipment [Line Items]
Antidilutive securities, earnings per share, amount						23,502
Share-Based Payment Arrangement, Option [Member]
Property, Plant and Equipment [Line Items]
Antidilutive securities, earnings per share, amount						147,783
Equity Incentive Plan 2021 - 2025 [Member]
Property, Plant and Equipment [Line Items]
Number of ordinary shares reserved						2,700,000

Schedule of prepaid expenses an

Schedule of prepaid expenses and other current assets (Details) - EUR (€)	Jun. 30, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Value Added Tax (VAT)	€ 1,072,002	€ 820,780
Research and development tax credit	800,000	600,000
Advances payments to suppliers	35,401	58,009
Other current assets	180,709	21,987
Other prepaids	648,996	18,247
Total	€ 2,737,108	€ 1,519,023

Prepaid expenses and other cu_3

Prepaid expenses and other current assets (Details Narrative) - EUR (€)	1 Months Ended	6 Months Ended
	Jan. 31, 2022	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Percentage of value added tax		22%		22%
Reimbursement of value added tax		€ 821,000
Value added tax receivable		1,072,002		€ 820,780
Research and development tax credit		4,200,000
Taxes payable, amount		306,000	€ 204,000
Research and development expense		1,640,579	3,199,234
Others assets current relate to tax credit		180,709		€ 21,987
Directors and Officers [Member] | Prepaid Expenses and Other Current Assets [Member]
Defined Benefit Plan Disclosure [Line Items]
Payment for insurance	€ 582,000
Prepayment registration fees		20,000
Prepaid expense		30,000
Research And Development Expense Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Research and development expense		706,000	€ 204,000
Italian Revenue Agency [Member]
Defined Benefit Plan Disclosure [Line Items]
Others assets current relate to tax credit		€ 180,000

Schedule of property and equipm

Schedule of property and equipment net (Details) - EUR (€)	Jun. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Computer	€ 20,353	€ 24,869
Auto	49,320
Furniture and fixtures	10,440	5,010
Total property and equipment	80,113	29,879
Less: accumulated depreciation	(14,185)	(6,789)
Property and equipment, net	€ 65,928	€ 23,090

Property and equipment, net (De

Property and equipment, net (Details Narrative) - EUR (€)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	€ 2,813	€ 2,086

Schedule of other non-current a

Schedule of other non-current assets (Details) - EUR (€)	Jun. 30, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Value Added Tax (VAT)		€ 641,215
Research and development tax credit	800,000	600,000
Total	€ 800,000	€ 1,241,215

Other non-current assets (Detai

Other non-current assets (Details Narrative) - EUR (€)	Jun. 30, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other non current assets related party	€ 3,350	€ 3,350

Retirement benefit obligation (

Retirement benefit obligation (Details Narrative) - EUR (€)	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Retirement Benefits [Abstract]
Deferred compensation for employees deferred compensation for employees	The annual accrual is approximately 7% of total pay, with no ceiling, and is revalued each year by applying a pre-established rate of return of 1.50%, plus 75% of the Consumer Price Index
Defined contribution plan, maximum annual contributions per employee, percent	7%
Retirement benefit obligation	€ 55,192	€ 30,618

Schedule of company_s capital o

Schedule of company’s capital ownership percentage (Details)	Dec. 31, 2020 EUR (€)
Quota A [Member]
Total	€ 10,458
Ownership percentage	28%
Quota B [Member]
Total	€ 6,886
Ownership percentage	19%
Quota C [Member]
Total	€ 8,645
Ownership percentage	23%
Quota D [Member]
Total	€ 4,034
Ownership percentage	11%
Quota E [Member]
Total	€ 7,033
Ownership percentage	19%
Consolidated quota [Member]
Total	€ 37,056
Ownership percentage	100%

Stockholders_ equity (Details N

Stockholders’ equity (Details Narrative) € / shares in Units, shares in Millions			1 Months Ended	6 Months Ended		12 Months Ended
	May 20, 2021 EUR (€) shares	Apr. 01, 2021 EUR (€) € / shares	Apr. 30, 2021 EUR (€)	Jun. 30, 2022 EUR (€)	Jun. 30, 2021 EUR (€)	Dec. 31, 2020 EUR (€)	Dec. 31, 2019 EUR (€)	Dec. 31, 2017 EUR (€)	Dec. 31, 2015 EUR (€)	Jun. 30, 2022 $ / shares
Schedule of Equity Method Investments [Line Items]
Corporate capital, percentage						100%
Proceeds from divestiture of businesses						€ 50,000,000
Stock issued during period value stock options exercised			€ 715		€ 715
Repurchased during period value					172
Proceeds from stock options exercised					715
Quota per share | $ / shares										$ 5.41
Capital units		€ 37,771				€ 37,056
Stock issued during period value conversion of units	€ 50,000
Additional paid in capital	€ 37,139,431
Conversion of stock shares issued | shares	15
Quota percentage of ownership	300%
Share based compensation				€ 240,043	€ 497,104
Quota A [Member]
Schedule of Equity Method Investments [Line Items]
Common stock, voting rights						Quota A had voting rights
Quota B [Member]
Schedule of Equity Method Investments [Line Items]
Common stock, voting rights						Quota B had no voting rights
Nominal amount						€ 1
Stock issued during period value stock options exercised		715				715
Repurchased during period value		172
Proceeds from stock options exercised		€ 543
Quota per share | € / shares		€ 1
Quota C [Member]
Schedule of Equity Method Investments [Line Items]
Proceeds from capital funding									€ 10,000,000
Quota D [Member]
Schedule of Equity Method Investments [Line Items]
Proceeds from capital funding								€ 7,000,000
Quota E [Member]
Schedule of Equity Method Investments [Line Items]
Proceeds from capital funding						1,400,000	€ 14,800,000
Financial fees gross						1,500,000	15,100,000
Financial fees net						€ 100,000	€ 300,000

Schedule of outstanding stock o

Schedule of outstanding stock options (Details) - EUR (€)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Share-Based Payment Arrangement [Abstract]
Number of options outstanding, Beginning		546
Weighted average exercise price outstanding, Beginning		€ 1
Weighted average remaining contractual term outstanding, Beginning		1 year
Aggregate intrinsic value outstanding, Beginning		€ 584,132
Number of options exercisable, Beginning
Weighted average exercise price exercisable, Beginning
Aggregate intrinsic value exercisable, Beginning
Number of options granted		169
Weighted average exercise price granted		€ 1
Aggregate intrinsic value granted		€ 183,831
Number of options vested and exercised		715
Weighted average exercise price vested and exercised		€ 1
Aggregate intrinsic value vested and exercised		€ 777,920
Number of options outstanding, Ending	147,783
Weighted average exercise price outstanding, Ending	€ 6.38
Aggregate intrinsic value outstanding, Ending	€ 29,878
Number of options exercisable, Ending	147,783
Weighted average exercise price exercisable, Ending	€ 6.38
Aggregate intrinsic value exercisable, Ending	€ 29,878
Number of options granted and immediately vested	147,783
Weighted average exercise price granted and immediately vested	€ 6.38
Weighted average remaining contractual term granted and immediately vested	2 years
Aggregate intrinsic value granted and immediately vested
Number of options cancelled or forfeited
Weighted average exercise price cancelled or forfeited
Aggregate intrinsic value cancelled or forfeited
Weighted Average Remaining Contractual Term exercisable, Ending	1 year 9 months 25 days

Schedule of share based compens

Schedule of share based compensation expenses (Details)	6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2022 EUR (€)	Jun. 30, 2021 EUR (€)
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 256,222	€ 240,043	€ 497,104
Unrecognized expense
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total			82,669
Research And Development Expense Related Party [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total			179,480
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total		€ 240,043	€ 234,955

Share-based compensation (Detai

Share-based compensation (Details Narrative)		1 Months Ended		6 Months Ended
	Apr. 26, 2022 € / shares shares	May 31, 2021 shares	Apr. 30, 2021 EUR (€)	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2022 EUR (€) € / shares shares	Jun. 30, 2021 EUR (€) € / shares shares	Jun. 30, 2022 EUR (€) € / shares	Dec. 31, 2021 EUR (€) € / shares	Dec. 31, 2020 EUR (€)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option price per share | € / shares	€ 6.38				€ 1
Stock Repurchased During Period, Value						€ 172
Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture			€ 169
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value			546				€ 29,878		€ 584,132
Stock Issued During Period, Value, Stock Options Exercised			715			715
Stock Issued During Period, Shares, Issued for Services | shares		2,700,000
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum		10%
Number of options granted and immediately vested | shares	147,783
Vested shares				$ 256,222	€ 240,043	497,104
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value					€ 240,043	€ 497,104
Weighted average fair value of options granted | € / shares					€ 1.62	€ 1,088
Option term	2 years
Expiration date	Apr. 26, 2024
Share price | $ / shares				$ 5.41
Exercise price | (per share)				$ 6.81	€ 6.38
Exchange rate				1.0674	1.0674
Expected term to maturity				18 months	18 months
Risk free interest rate				2.27%	2.27%
Volatility rate, percentage				82%	82%
Weighted average of ordinary shares | shares				18,216,858	18,216,858	14,772,610
Common stock, par value | € / shares							€ 0	€ 0
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock Repurchased During Period, Value			€ 172
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period				1 year	1 year
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period				3 years	3 years

Schedule of third party and rel

Schedule of third party and related party expenses (Details) - EUR (€)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Related Party Transaction [Line Items]
Total	€ 1,640,579	€ 3,199,234
Consultants and Other Third Parties [Member]
Related Party Transaction [Line Items]
Total	338,265	2,067,504
Materials And Supplies [Member]
Related Party Transaction [Line Items]
Total	837,098	717,905
Compensation [Member]
Related Party Transaction [Line Items]
Total	377,928	401,380
Travel And Entertainment [Member]
Related Party Transaction [Line Items]
Total	65,938	10,445
Other [Member]
Related Party Transaction [Line Items]
Total	21,350	2,000
Third Parties [Member]
Related Party Transaction [Line Items]
Total	1,384,818	1,478,228
Third Parties [Member] | Consultants and Other Third Parties [Member]
Related Party Transaction [Line Items]
Total	298,265	525,978
Third Parties [Member] | Materials And Supplies [Member]
Related Party Transaction [Line Items]
Total	837,098	717,905
Third Parties [Member] | Compensation [Member]
Related Party Transaction [Line Items]
Total	162,167	221,900
Third Parties [Member] | Travel And Entertainment [Member]
Related Party Transaction [Line Items]
Total	65,938	10,445
Third Parties [Member] | Other [Member]
Related Party Transaction [Line Items]
Total	21,350	2,000
Related Parties [Member]
Related Party Transaction [Line Items]
Total	255,761	1,721,006
Related Parties [Member] | Consultants and Other Third Parties [Member]
Related Party Transaction [Line Items]
Total	40,000	1,541,526
Related Parties [Member] | Materials And Supplies [Member]
Related Party Transaction [Line Items]
Total
Related Parties [Member] | Compensation [Member]
Related Party Transaction [Line Items]
Total	215,761	179,480
Related Parties [Member] | Travel And Entertainment [Member]
Related Party Transaction [Line Items]
Total
Related Parties [Member] | Other [Member]
Related Party Transaction [Line Items]
Total

Schedule of third party and gen

Schedule of third party and general and administrative expenses (Details) - EUR (€)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Related Party Transaction [Line Items]
Total	€ 2,513,558	€ 842,236
Compensation [Member]
Related Party Transaction [Line Items]
Total	943,570	408,514
Accounting Legal and Other Professional [Member]
Related Party Transaction [Line Items]
Total	376,642	181,354
Facility and Insurance Related [Member]
Related Party Transaction [Line Items]
Total	11,330	8,909
Consultants and Other Third Parties [Member]
Related Party Transaction [Line Items]
Total	384,243	127,988
Other [Member]
Related Party Transaction [Line Items]
Total	797,773	115,471
Third Parties [Member]
Related Party Transaction [Line Items]
Total	2,081,018	685,039
Third Parties [Member] | Compensation [Member]
Related Party Transaction [Line Items]
Total	522,012	258,514
Third Parties [Member] | Accounting Legal and Other Professional [Member]
Related Party Transaction [Line Items]
Total	376,642	181,354
Third Parties [Member] | Facility and Insurance Related [Member]
Related Party Transaction [Line Items]
Total	3,873	1,712
Third Parties [Member] | Consultants and Other Third Parties [Member]
Related Party Transaction [Line Items]
Total	384,243	127,988
Third Parties [Member] | Other [Member]
Related Party Transaction [Line Items]
Total	794,248	115,471
Related Parties [Member]
Related Party Transaction [Line Items]
Total	432,540	157,197
Related Parties [Member] | Compensation [Member]
Related Party Transaction [Line Items]
Total	421,558	150,000
Related Parties [Member] | Accounting Legal and Other Professional [Member]
Related Party Transaction [Line Items]
Total
Related Parties [Member] | Facility and Insurance Related [Member]
Related Party Transaction [Line Items]
Total	7,457	7,197
Related Parties [Member] | Consultants and Other Third Parties [Member]
Related Party Transaction [Line Items]
Total
Related Parties [Member] | Other [Member]
Related Party Transaction [Line Items]
Total	€ 3,525

Schedule of accounts payable to

Schedule of accounts payable to related parties (Details) - EUR (€)	Jun. 30, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Total	€ 277,654	€ 25,047
San raffaele hospital [Member]
Related Party Transaction [Line Items]
Total	265,616	25,047
Carlo russo [Member]
Related Party Transaction [Line Items]
Total	8,208
Richard Slansky [Member]
Related Party Transaction [Line Items]
Total	€ 3,830

Schedule of accrued expenses to

Schedule of accrued expenses to related parties (Details) - EUR (€)	Jun. 30, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Total	€ 172,359	€ 132,141
San raffaele hospital Osr [Member]
Related Party Transaction [Line Items]
Total	172,359	19,201
Executive bonus [Member]
Related Party Transaction [Line Items]
Total		25,000
Xdg biomed [Member]
Related Party Transaction [Line Items]
Total		34,438
Financial consultant [Member]
Related Party Transaction [Line Items]
Total		€ 53,502

Related parties (Details Narrat

Related parties (Details Narrative)

1 Months Ended

6 Months Ended

12 Months Ended

Dec. 17, 2021 EUR (€)

Dec. 16, 2021 EUR (€)

Nov. 02, 2021 EUR (€)

Apr. 30, 2021 EUR (€)

Feb. 28, 2021 EUR (€)

Jun. 30, 2022 EUR (€)

Jun. 30, 2021 EUR (€)

Dec. 31, 2020 EUR (€)

Dec. 31, 2019 EUR (€)

Dec. 31, 2015 EUR (€)

Apr. 30, 2022 EUR (€)

Dec. 31, 2021 USD ($)

Dec. 31, 2021 EUR (€)

Related Party Transaction [Line Items]

Percentage of annual bonus

30%

Accrued Bonuses

€ 25,000

Annual gross salary

€ 500,000

Due from Related Parties

35,401

€ 58,009

Share-Based Payment

197,500

Other Comprehensive Income (Loss), Tax

€ 105,551

Minimum [Member]

Related Party Transaction [Line Items]

Royalty fee percentage

0.50%

Maximum [Member]

Related Party Transaction [Line Items]

Royalty fee percentage

1%

Investigator [Member]

Related Party Transaction [Line Items]

Share-Based Payment

€ 105,000

Data manager [Member]

Related Party Transaction [Line Items]

Share-Based Payment

92,500

First Indication [Member]

Related Party Transaction [Line Items]

Future option fees

1,000,000

Decreased future option fees

500,000

Second Indication [Member]

Related Party Transaction [Line Items]

Future option fees

500,000

Third Indication [Member]

Related Party Transaction [Line Items]

Future option fees

€ 300,000

First Solid Cancer Indication [Member]

Related Party Transaction [Line Items]

Option fee

€ 500,000

Second Solid Cancer Indication [Member]

Related Party Transaction [Line Items]

Option fee

€ 500,000

License Agreement Amendment One [Member]

Related Party Transaction [Line Items]

Upfront fee

€ 250,000

Royalty fee percentage

4%

License Agreement Amendment Two [Member]

Related Party Transaction [Line Items]

Repayments of Related Party Debt

€ 1,000,000

License Agreement Amendment Two [Member] | San raffaele hospital [Member]

Related Party Transaction [Line Items]

Costs and Expenses, Related Party

300,000

800,000

License Agreement Amendment Three [Member]

Related Party Transaction [Line Items]

Repayments of Related Party Debt

1,250,000

Payments for merger related costs gross

1,000,000

License Agreement Amendment Three [Member] | Minimum [Member]

Related Party Transaction [Line Items]

Payments for merger related costs gross

€ 500,000

License Agreement Amendment Four [Member] | First Solid Cancer Indication Option Fee [Member]

Related Party Transaction [Line Items]

Interest expense

9,000,000

License Agreement Amendment Four [Member] | Second solid cancer indication option fee [Member]

Related Party Transaction [Line Items]

Interest expense

1,000,000

License Agreement Amendment Five [Member]

Related Party Transaction [Line Items]

Milestone payment

350,000

Sponsor Research Agreement [Member]

Related Party Transaction [Line Items]

Interest expense, related party

375,000

500,000

Option fee

€ 1,000,000

Reduction in option fee

500,000

Sponsor Research Agreement [Member] | Minimum [Member]

Related Party Transaction [Line Items]

Sponsored research activities

500,000

Sponsor Research Agreement [Member] | Maximum [Member]

Related Party Transaction [Line Items]

Sponsored research activities

€ 1,000,000

Pierluigi Paracchi [Member]

Related Party Transaction [Line Items]

Salary and Wage, Officer, Excluding Cost of Good and Service Sold

€ 250,000

Annual performance bonus

€ 50,000

Salary and Wage, Excluding Cost of Good and Service Sold

€ 420,000

Percentage of annual bonus

20%

Accrued Bonuses

37,000

23,000

€ 50,000

Interest expense, related party

248,242

150,000

Retirement benefit obligation

14,000

Naldini [Member]

Related Party Transaction [Line Items]

Annual fee

50,000

Prepaid expense

25,000

25,000

Gentner [Member]

Related Party Transaction [Line Items]

Annual fee

30,000

Prepaid expense

15,000

15,000

XDG Biomed LLC [Member]

Related Party Transaction [Line Items]

Recurring fees

300,000

Employee-related Liabilities

50,000

Related expense

215,761

175,000

Other Comprehensive Income (Loss), Tax

€ 179,480

Richard Slansky [Member]

Related Party Transaction [Line Items]

Percentage of annual bonus

30%

Accrued Bonuses | $

$ 50,000

Other Comprehensive Income (Loss), Tax

€ 54,388

Due from Related Parties

€ 42,224

Gross annual compensation

€ 300,000

Contribution of Property

€ 173,317

Spafid SPA [Member]

Related Party Transaction [Line Items]

Equity method investment ownership percentage

5%

Due from Related Parties

€ 3,525

San raffaele hospital [Member]

Related Party Transaction [Line Items]

Equity method investment ownership percentage

5%

Schedule of company obligations

Schedule of company obligations by contractual maturity (Details)	Jun. 30, 2022 EUR (€)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total	€ 142,353
Payments by period, less than a year	28,446
Payments by period, one to three years	96,907
Payments by period, four to five years	17,000
Payments by period, more than five years
OSR Operating Leases And Office Rent [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total	33,500
Payments by period, less than a year	13,400
Payments by period, one to three years	20,100
Payments by period, four to five years
Payments by period, more than five years
AGC Manufacturing [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total	83,200
Payments by period, less than a year	8,050
Payments by period, one to three years	58,150
Payments by period, four to five years	17,000
Payments by period, more than five years
Insurance on operating leases [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total	25,653
Payments by period, less than a year	6,996
Payments by period, one to three years	18,657
Payments by period, four to five years
Payments by period, more than five years

Commitments and contingencies_2

Commitments and contingencies (Details Narrative) - EUR (€)	1 Months Ended						3 Months Ended	6 Months Ended		12 Months Ended
	Jan. 31, 2023	Oct. 31, 2021	Oct. 31, 2020	Aug. 31, 2020	Mar. 31, 2020	Feb. 29, 2020	Mar. 31, 2022	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Loss Contingencies [Line Items]
Payment for license fee								€ 5,000,000
Contingent payments								47,500,000
Debt Related Commitment Fees and Debt Issuance Costs								7,800,000
Other Expenses								800,000	€ 700,000
Cumulative manufacturing expense								6,200,000
Production Costs, Period Cost			€ 17,000
Payments for Rent								13,400
Amortization expenses								4,583
Property, Plant and Equipment, Net								44,737
Lease current								12,330
Non current liabilities								32,407
Finance lease								27,985
Insurance costs								2,332
Outstanding payment insurance								25,653
Subsequent Event [Member]
Loss Contingencies [Line Items]
Lease, Cost	€ 6,700
Minimum [Member]
Loss Contingencies [Line Items]
Loss contingency								€ 500,000
Royalty fee percentage								0.50%
Maximum [Member]
Loss Contingencies [Line Items]
Loss contingency								€ 1,000,000
Royalty fee percentage								1%
Related Milestone One [Member]
Loss Contingencies [Line Items]
Debt instrument, periodic payment								€ 7,000,000
Related Milestone Two [Member]
Loss Contingencies [Line Items]
Debt instrument, periodic payment								3,500,000
OSR [Member]
Loss Contingencies [Line Items]
Debt instrument, periodic payment								53,000,000
Contingent consideration, liability											€ 53,000,000
Lympho hematopoietic [Member]
Loss Contingencies [Line Items]
Potential milestone payments								10,000,000
AGC Biologics Agreement [Member]
Loss Contingencies [Line Items]
Potential milestone payments								300,000
Total commitment amount									€ 51,000
Total commitment								83,200
AGC Agreement [Member]
Loss Contingencies [Line Items]
Cumulative manufacturing expense								1,000,000
Technology transfer fee								500,000
Amendment Four [Member]
Loss Contingencies [Line Items]
Production Costs, Period Cost						€ 360,000
Amendment Five [Member]
Loss Contingencies [Line Items]
Production Costs, Period Cost					€ 259,000
Production costs percentage				20%
Amendment Six [Member]
Loss Contingencies [Line Items]
Production Costs, Period Cost					€ 41,000
Amendment Seven [Member]
Loss Contingencies [Line Items]
Production Costs, Period Cost				€ 259,000
GMP Batch [Member]
Loss Contingencies [Line Items]
Cumulative manufacturing expense		€ 311,280
LVV Batch [Member]
Loss Contingencies [Line Items]
Cumulative manufacturing expense										€ 311,280
Frame work service agreement [Member]
Loss Contingencies [Line Items]
Cumulative manufacturing expense							€ 272,800
Service Agreement [Member]
Loss Contingencies [Line Items]
Production Costs, Period Cost											€ 300,000
Total commitment amount								€ 32,200

Subsequent events (Details Narr

Subsequent events (Details Narrative) - shares	Jul. 21, 2022	Apr. 26, 2022
Subsequent Event [Line Items]
Non qualified stock options		147,783
Subsequent Event [Member] | Employees and Directors [Member]
Subsequent Event [Line Items]
Non qualified stock options	392,740